WO2005122902A1 - Method and apparatus for individual intraventricular delay optimization - Google Patents

Method and apparatus for individual intraventricular delay optimization Download PDF

Info

Publication number
WO2005122902A1
WO2005122902A1 PCT/US2005/019773 US2005019773W WO2005122902A1 WO 2005122902 A1 WO2005122902 A1 WO 2005122902A1 US 2005019773 W US2005019773 W US 2005019773W WO 2005122902 A1 WO2005122902 A1 WO 2005122902A1
Authority
WO
WIPO (PCT)
Prior art keywords
pacing
heart sound
dyssynchrony
parameter
heart
Prior art date
Application number
PCT/US2005/019773
Other languages
French (fr)
Inventor
Marina Brockway
William C. Lincoln
Gerrard M. Carlson
Original Assignee
Cardiac Pacemakers, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiac Pacemakers, Inc. filed Critical Cardiac Pacemakers, Inc.
Priority to EP05758855.0A priority Critical patent/EP1768566B1/en
Priority to JP2007527615A priority patent/JP4939417B2/en
Publication of WO2005122902A1 publication Critical patent/WO2005122902A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/05Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/053Measuring electrical impedance or conductance of a portion of the body
    • A61B5/0538Measuring electrical impedance or conductance of a portion of the body invasively, e.g. using a catheter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B7/00Instruments for auscultation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/365Heart stimulators controlled by a physiological parameter, e.g. heart potential
    • A61N1/36514Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/08Detecting, measuring or recording devices for evaluating the respiratory organs
    • A61B5/0809Detecting, measuring or recording devices for evaluating the respiratory organs by impedance pneumography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/103Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
    • A61B5/113Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb occurring during breathing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7203Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/7253Details of waveform analysis characterised by using transforms
    • A61B5/726Details of waveform analysis characterised by using transforms using Wavelet transforms
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F2218/00Aspects of pattern recognition specially adapted for signal processing

Definitions

  • Patent Application Serial No. 10/334,694 entitled “METHOD AND APPARATUS FOR MONITORING OF DIASTOLIC HEMODYNAMICS,” filed December 30, 2002, and U.S. Patent Application Serial No. 10/307,896, "PHONOCARDIOGRAPHIC IMAGE-BASED ATRIOVENTRICULAR DELAY OPTIMIZATION,” filed December 2, 2002, which are hereby incorporated by reference in their entirety.
  • CRM cardiac rhythm management
  • the heart is the center of a person's circulatory system. It includes a complex electro-mechanical system performing two major pumping functions.
  • the heart includes four chambers: right atrium (RA), right ventricle (RV), left atrium (LA), and left ventricle (LV).
  • the RA draws deoxygenated blood from organs of the body and injects it into the RV through the tricuspid valve.
  • the RV pumps the deoxygenated blood to the lungs through the pulmonary valve.
  • the blood gets oxygenated in the lungs.
  • the LA draws oxygenated blood from the lungs and injects it into the LV through the mitral valve.
  • the LV pumps the oxygenated blood to the organs of the body, through the aortic valve, to provide the organs with their metabolic needs for oxygen.
  • SA siiioatrial
  • action potentials electrical impulses
  • the muscles in various regions of the heart to contract in mechanical synchrony such that the pumping functions are performed efficiently.
  • the normal pumping functions of the heart require a normal electrical system to generate the action potentials and deliver them to designated portions of the myocardium with proper timing, a normal myocardium capable of contracting with sufficient strength, and a normal electro-mechanical association such that all regions of the heart are excitable by the action potentials.
  • a blocked or otherwise abnormal electrical conduction and/or deteriorated myocardial tissue cause dysynchronous contraction of the heart, resulting in poor hemodynamic performance, including a diminished blood supply to the heart and the rest of the body.
  • the condition where the heart fails to pump enough blood to meet the body's metabolic needs is known as heart failure.
  • the pumping functions are mechanical functions, the hemodynamic performance is ultimately determined by the mechanical synchrony of the heart. For this and other reasons, there is a need for a direct assessment of cardiac mechanical dyssynchrony. The assessment serves as a direct measure of efficacy for a cardiac therapy restoring the cardiac mechanical synchrony.
  • a cardiac rhythm management (CRM) system provides for assessment of cardiac mechanical dyssynchrony based on heart sound morphology and optimization of pacing parameters based on the effect of pacing on the cardiac mechanical dyssynchrony assessment.
  • a degree of cardiac mechanical dyssynchrony is measured by the time delay between tricuspid valve closure and mitral valve closure and or the time delay between pulmonary valve closure and aortic valve closure.
  • a cardiac ⁇ synchronization therapy is optimized by determining therapy parameters to provide an approximately minimum degree of cardiac mechanical dyssynchrony by cardiac pacing.
  • a system for analyzing a heart includes a heart sound input, a heart sound detector, and a computer-based heart sound morphology analyzer.
  • the heart sound input receives one or more signals indicative of heart sounds.
  • the heart sound detector detects heart sounds of at least one predete ⁇ nined type.
  • the computer-based heart sound morphology analyzer produces at least one dyssynchrony parameter indicative of a degree of cardiac mechanical dyssynchrony based on measurements of the detected heart sounds.
  • the heart sound morphology analyzer includes a heart sound measurement module to measure one or more parameters each based on at least one morphological feature of the detected heart sounds.
  • the morphological feature indicates a time interval between closures of a first cardiac valve and a second cardiac valve of the heart in one cardiac cycle.
  • a system for analyzing a heart includes an implantable system and an external system communicating with the implantable system.
  • the implantable system includes one or more implantable heart sound sensors and an implantable medical device.
  • the one or more implantable heart sound sensors sense one or more heart sound signals each indicative of heart sounds.
  • the implantable medical device includes an implant controller to process the one or more heart sound signals and an implant telemetry module to transmit the one or more heart sound signals to the external system.
  • the external system includes an external telemetry module to receive the one or more heart sound signals and an external controller to process the one or more heart sound signals.
  • the external controller includes a heart sound morphology analyzer to produce at least one dyssynchrony parameter indicative of a degree of cardiac mechanical dyssynchrony.
  • the heart sound morphology analyzer includes a heart sound measurement module to measure one or more parameters each based on at least one morpho logical feature of heart sounds of at least one predetermined type.
  • the morphological feature indicates a time interval between closures of a first cardiac valve and a second cardiac valve of a heart in one cardiac cycle.
  • a method for operating a cardiac pacemaker is provided.
  • One or more heart sound signals indicative of heart sounds are received.
  • Heart sounds of at least one predetermined type are detected.
  • One or more dyssynchrony parameters each indicative of a degree of cardiac mechanical dyssynchrony are produced based on at least one morphological feature of the detected heart sounds by executing an automated cardiac mechanical dyssynchrony algorithm.
  • One or more pacing parameters for minimizing the degree of cardiac mechanical dyssynchrony are detennined based on the one or more dyssynchrony parameters.
  • FIG. 1 is a graph illustrating a sensed heart sound signal before and after envelope detection.
  • FIG. 2 is a graph illustrating heart sound signals indicative of cardiac mechanical synchrony sensed by various heart sound sensors.
  • FIG. 3 is a graph illustrating heart sound signals indicative of cardiac mechanical dyssynchrony sensed by various heart sound sensors.
  • FIG. 4 is a block diagram illustrating one embodiment of a system for optimizing pacing parameters based on a cardiac mechanical dyssynchrony assessment.
  • FIG. 5 is an illustration of one embodiment of a CRM system and portions of the environment in which the CRM system is used.
  • FIG. 6 is a block diagram illustrating one embodiment of a circuit of the CRM system.
  • FIG. 7 is a flow chart illustrating one embodiment of a method for optimizing pacing parameters based on the cardiac mechanical dyssynchrony assessment.
  • Heart sounds or generally energies resulted from the heart's mechanical vibrations, indicate the heart's mechamcal activities, including the openings and closures of the tricuspid, pulmonary, mitral, and aortic valves.
  • heart sounds provide a direct measure of efficacy for a therapy intended to restore the heart's ability to contract in synchrony.
  • heart sound includes audible and inaudible mechanical vibrations caused by cardiac mechamcal activities that can be sensed with an accelerometer.
  • SI generally refers to a heart sound type known as the "first heart sound,” or as one or more occurrences or instances of the first heart sound, depending on the context.
  • S2 generally refers to a heart sound type known as the "second heart sound,” or as one or more occurrences or instances of the second heart sound, depending on the context.
  • FIG. 1 is a graph illustrating a sensed heart sound signal 100 and a processed heart sound signal 102 over one cardiac cycle. Both signals 100 and 102 indicate SI and S2.
  • Sensed heart sound signal 100 represents an output of a heart sound sensor such as an accelerometer sensing the heart's mechanical vibrations or a microphone sensing audible sound originated from the heart. The signal is conditioned by at least envelope detection to produce heart sound signal 102.
  • a "heart sound signal” refers to either a heart sound signal as an output of a heart sound sensor, such as illustrated by signal 100, or a heart sound signal that has been envelope detected, such as illustrated by signal 102.
  • Each cardiac cycle includes a diastolic phase, during which blood fills the RV through the tricuspid valve and the LV through mitral valve, and a systolic phase, during which the blood are ejected from the RV through the pulmonary valve and the LV through the aortic valve.
  • SI is known to originate from, among other things, the mechanical vibrations associated with tricuspid valve closure and mitral valve closure, which start the diastolic phase.
  • FIG. 2 is a graph illustrating heart sound signals indicative of cardiac mechanical synchrony sensed by various heart sound sensors over a cardiac cycle.
  • a "global" heart sound signal 202G is sensed by a single heart sound sensor sensing heart sounds originated from the entire heart.
  • Heart sound signal 202G indicates SI G (global SI) and S2 G (global S2) for heart that contracts synchronously.
  • SI G global SI
  • S2 G global S2 G
  • S2Q is morphologically characterized by a single peak and an S2 width 212 that falls within the normal S2 width range.
  • "Regional" heart sound signals 202R and 202L are sensed simultaneously using two sensors each primarily sensing heart sounds originated from one portion of the heart, such as the right portion or the left portion.
  • heart sound signal 202R is sensed by a heart sound sensor placed within the RV
  • heart sound signal 202L is sensed by a heart sound sensor placed within the LV.
  • RV heart sound signal 202R indicates S1 RV (SI sensed in the RV) and S2R V (S2 sensed in the RV).
  • SIRV indicates tricuspid valve closure.
  • S2 R v indicates pulmonary valve closure.
  • LV heart sound signal 202L indicates Sl L v (SI sensed in the LV) and S2 L v (S2 sensed in the LV).
  • S1 LV indicates mitral valve closure.
  • S2LV indicates aortic valve closure.
  • SIR V tricuspid valve closure
  • SI LV mitral valve closure
  • the sounds of tricuspid valve closure and mitral valve closure substantially overlap, producing the normal S1 G - Pulmonary valve closure (S2 R V) and aortic valve closure (S2 R V) occur substantially simultaneously.
  • the sounds of pulmonary valve closure and aortic valve closure substantially overlap, producing the normal S2 G .
  • FIG. 3 is a graph illustrating heart sound signals indicative of cardiac mechanical dyssynchrony sensed by various heart sound sensors over a cardiac cycle.
  • a "global" heard sound signal 302G is sensed by a single heart sound sensor sensing heart sounds originated from the entire heart.
  • "Regional" heart sound signals 302R and 302L are sensed simultaneously using two sensors each primarily sensing heart sounds originated from one portion of the heart.
  • Heart sound signal 302G corresponds to heart sound signal 202G
  • heart sound signal 302R corresponds to heart sound signal 202R
  • heart sound signal 302L corresponds to heart sound signal 202L.
  • signals 202G, 202R, and 202L illustrates heart sound signals indicative cardiac synchrony
  • signals 302G, 302R, and 302L illustrates heart sound signals indicative cardiac dyssynchrony.
  • S IRV tricuspid valve closure
  • S ILV mitral valve closure
  • a delay 316 between pulmonary valve closure (S2RV) and aortic valve closure (S2LV) indicates that the pulmonary valve and the aortic valve no longer close substantially simultaneously.
  • the delay results in a double peaked S2G, and/or an abnormally large 82 width 312 associated with S2Q.
  • a heart that fails to contract in synchrony may be indicated by one or more of delay 314 and delay 316 and/or one or more of SI width 310 and S2 width 312. It is to be understood that the relative timing between SIRV and SILV and the relative timing between S2 R and S2 L v as shown in FIG. 3 represents an example for illustrative purpose only.
  • FIG. 3 represents an example for illustrative purpose only.
  • FIG. 3 shows exemplary heart sound signals of a patient suffering left bundle branch block (LBBB), in which SIRV leads Sl L v in time, and S2R V leads S2LV in time.
  • LBBB left bundle branch block
  • SIRV leads Sl L v in time
  • S2R V leads S2LV in time.
  • the system and method discussed below are generally applicable to cardiac mechanical dyssynchrony indicated by any one or more of delay 314, delay 316, an abnormally long SI width 310, and an abnormally long S2 width 312.
  • An effective treatment to resynchronize the heart shortens or eliminates either or both delays 314 and 316 and restores both widths 310 and 312 to their normal values.
  • the goals of the treatment include (i) merging the two peaks of S1Q, and merging the two peaks of S2 G , or (ii) realigning SIRV and SILV, and realigning S2RV and S2 L V-
  • higher priority is given to the goal of (i) merging the two peaks of S2G, or (ii) realigning S2 RV and S2L V -
  • CRT cardiac resynchronization therapy
  • the extent to which a therapy restores cardiac synchrony is indicated by the extent to which delay 314 or 316 are reduced, or by the extent to which width 310 and 312 returned to their normal values.
  • heart sound signals 302G In system and method descriptions below, heart sound signals 302G,
  • Heart sound signal 302G generally includes a "global" heart sound sensed by a single sensor and indicative of heart sounds originating from anywhere in the heart.
  • Heart sound signals 302R and 302L include two heart sound signals simultaneously by two sensors.
  • Heart sound signal 302R generally includes a "regional" heart sound indicative of primarily heart sounds originating from the right side of the heart, sensed by such as a sensor placed in the RV.
  • Heart sound signal 302L generally includes another "regional" heart sound indicative of primarily heart sounds originating from the left side of the heart, sensed by such as a sensor placed in the LV.
  • S1G generally includes a heart sound resulted from a combination of tricuspid valve closure and mitral valve closure.
  • S2 G generally includes a heart sound resulted from a combination of pulmonary valve closure and aortic valve closure.
  • S IRV generally includes a heart sound resulted from tricuspid valve closure.
  • S2 R V generally includes a heart sound resulted from pulmonary valve closure.
  • SILV generally includes a heart sound resulted from mitral valve closure.
  • S2LV generally includes a heart sound resulted from aortic valve closure.
  • FIG. 4 is a block diagram illustrating one embodiment of a system 400 for optimizing pacing parameters based on a cardiac mechamcal dyssynchrony assessment.
  • System 400 includes a heart sound sensor 402, a heart sound signal processor 403, a respiratory sensor 404, a respiratory signal processor 405, a cardiac mechanical dyssynchrony assessment module 410, a pacing parameter optimization module 430, a pacing controller 432, and a pacing circuit 434.
  • portions of system 400 are implemented as a computer-based system.
  • Heart sound sensor 402 includes one or more sensors each sense a signal indicative of heart sounds. Examples of the one or more sensors include accelerometers and microphones.
  • heart sound sensor 402 includes a single heart sound sensor to sense a heart sound signal 302G. In one specific embodiment, the single heart sound sensor is placed external to the heart. In another specific embodiment, the single heart sound sensor is placed within a heart chamber.
  • heart sound sensor 402 is a sensor system including a plurality of heart sound sensors each sensing a signal indicative of heart sounds originating from a particular portion of the heart.
  • the plurality of heart sound sensors include an Ry heart sound sensor to sense heart sound signal 302R and an LV heart sound sensor to sense heart sound signal 302L.
  • the RV heart sound sensor is an intracardiac heart sound sensor for placement in the RV to sense a heart sound signal indicative of at least tricuspid valve closure and pulmonary valve closure
  • the LV heart sound sensor is another intracardiac heart sound sensor for placement in the LV to sense a heart sound signal indicative of at least mitral valve closure and aortic valve closure.
  • the RV heart sound sensor is the intracardiac heart sound sensor for placement in the RV to sense the heart sound signal indicative of at least tricuspid valve closure and pulmonary valve closure
  • the LV heart sound sensor is an epicardial heart sound sensor for placement on the epicardial wall over the LV to sense a heart sound signal indicative of at least mitral valve closure and aortic valve closure.
  • Heart sound signal processor 403 conditions the one or more heart sound signals sensed by heart sound sensor 402.
  • Heart sound signal processor 403 includes an envelope detector to produce heart sound signal 302G and/or heart sound signals 302R and 302L.
  • heart sound signal processor 403 further includes an ensemble averaging circuit to improve a signal-to-noise ratio of each of the one or more heart sound signals by ensemble averaging.
  • Respiratory sensor 404 senses a respiratory signal indicative of respiratory cycles each including an inspiratory phase and expiratory phase.
  • respiratory sensor 404 includes an accelerometer sensing an acceleration signal indicative of inspiration and expiration.
  • respiratory sensor 404 includes a minute ventilation sensor.
  • the minute ventilation sensor is an implantable impedance sensor sensing a thoracic impedance indicative of minute ventilation.
  • Respiration signal processor 405 conditions the respiratoiy signal for use by cardiac mechanical dyssynchrony assessment module 410.
  • respiration signal processor 405 includes an expiration detector to detect and indicate each expiratory phase of the respiratory cycle.
  • Cardiac mechanical dyssynchrony assessment module 410 produces one or more dyssynchrony parameters each indicative of a degree of cardiac mechanical dyssynchrony based on at least the one or more heart sound signals sensed by heart sound sensor 402 and preprocessed by heart sound signal processor 403.
  • Cardiac mechanical dyssynchrony assessment module 410 includes a heart sound input 412, a respiratory signal input 413, a heart sound detector 414, and a heart sound morphology analyzer 420.
  • cardiac mechanical dyssynchrony assessment module 410 is implemented as a computer-based system.
  • cardiac mechamcal dyssynchrony assessment module 410 produces the one or more dyssynchrony parameters by executing an automated cardiac mechanical dyssynchrony algorithm using at least the one or more heard sound signals and/or detected SI and S2 as input.
  • Heart sound input 412 receives the one or more heart sound signals, such as heart sound signal 302G and/or heart sound signals 302R and 302L.
  • Respiratory signal input 413 receive the respiratory signal indicative of which occurrences of S2 G and/or S2RV and S2 V are detected during an expiratory phase.
  • Heart sound detector 414 detects heart sounds from the one or more heart sound signals.
  • Heart sound detector 414 includes at least an SI detector 416 and an S2 detector 418.
  • SI detector 416 detects S1G, and S2 detector 418 detects S2 G , both from heart sound signal 302G.
  • SI detector 416 detects SI R V fr m heart sound signal 302R and SI L V from heart sound signal 302L, and S2 detector 418 detects S2 R V from heart sound signal 302R and S2LV from heart sound signal 302L.
  • Heart sound morphology analyzer 420 produces one or more dyssynchrony parameters.
  • heart sound morphology analyzer 420 is a computer-based analyzer that produces the one or more dyssynchrony parameters by executing the automated cardiac mechanical dyssynchrony algorithm.
  • the automated cardiac mechanical dyssynchrony algorithm is designed to detect morphological features of detected SI and S2, make measurements related to the morphological features, and produce the one or more dyssynchrony parameters based on results of the measurements, as described below.
  • Heart sound morphology analyzer 420 includes at least an SI mo ⁇ hology analyzer 422 to produce a dyssynchrony parameter related to S1 G (or S IRV and SILV) and an S2 mo ⁇ hology analyzer 426 to produce another dyssynchrony parameter related to S2 G (or S2RV and S2LV)-
  • S2 mo ⁇ hology analyzer 426 to produce the dyssynchrony parameter related to S2G (or S2RV and S2 L V) based on only on S2G (or S2RV and S2LV) detected during an expiratory phase of the respiratory cycle.
  • Heart sound mo ⁇ hology analyzer 420 includes one or more heart sound measurement modules to measure parameters associated with the mo ⁇ hological features of the one or more heart sounds.
  • SI mo ⁇ hology analyzer 422 includes an SI measurement module 424.
  • S2 mo ⁇ hology analyzer 426 includes an S2 width measurement module 428.
  • each heart sound measurement module includes a heart sound width measurement module to measure widths of the heart sounds.
  • SI measurement module 424 includes an SI width measurement module to measure SI width 310 (the width of S1 G ).
  • S2 measurement module 428 includes an S2 width measurement module to measure S2 width 312 (the width of S2 G ).
  • each heart sound measurement module includes a heart sound delay measurement modules to measure delays in cardiac valve closure as indicated by heart sounds in a single heart sound signal such as heart sound signal 302G.
  • Each heart sound delay measurement module includes a peak detector and a timer. The peak detector detects peaks within a heart sound each indicating one valve closure. If two peaks are detected within the heart sound, the timer measures the delay as the time interval between the two peaks.
  • SI measurement module 424 includes an SI delay measurement measure to measure SI delay 314 as a time interval between two peaks detected within S1 G - S2 measurement module 428 includes an S2 delay measurement measure to measure S2 delay 316 as a time interval between two peaks detected within S2 G .
  • an imaging technique such as tissue Doppler imaging (TDI), echocardiography, or magnetic resonance imaging (MRI) is applied to differentiate between the two peaks of S1 G -
  • TDI tissue Doppler imaging
  • MRI magnetic resonance imaging
  • an imaging technique such as tissue Doppler imaging (TDI), echocardiography, or magnetic resonance imaging (MRI)
  • TDI tissue Doppler imaging
  • MRI magnetic resonance imaging
  • this fact is utilized to differentiate between the two peaks of S2Q.
  • each heart sound measurement modules of mo ⁇ hology analyzer 420 is calibrated on a periodic basis or as needed using these peak identification techniques.
  • each heart sound measurement module includes a heart sound delay measurement modules to measure delays in cardiac valve closure as indicated by heart sounds in two heart sound signals such as heart sound signals 302R and 302L.
  • Each heart sound delay measurement module includes a timer to measure the delay being a time interval between a heart sound detected in one heart sound signal and the heart sound detected in another heart sound signal.
  • SI measurement module 424 includes an S 1 delay measurement module to measure S 1 delay 314 as the time interval between SIR V and SI L V-
  • S2 measurement module 428 includes an S2 delay measurement module to measure S2 delay 316 as the time interval between S2RV and S2LV-
  • heart sound mo ⁇ hology analyzer 420 includes a heart sound time-frequency analyzer to produce at least one time-frequency representation for each of the one or more heart sound signals and produce the one or more dyssynchrony parameters each associated with at least one feature of the one time-frequency representation.
  • the heart sound time-frequency analyzer further produces a parameter indicative of pulmonary artery pressure based on at least one feature of the time-frequency representation.
  • the heart sound time-frequency analyzer includes, by way of example, and not by way of limitation, one or more of a short-time Fourier transform (STFT) module, a reduced interference (RID) module, and a wavelet transform (WT) module.
  • STFT short-time Fourier transform
  • RID reduced interference
  • WT wavelet transform
  • the STFT module produces a time versus frequency representation of the signal by applying a sliding window to data representing the one or more heart sound signals.
  • a spectral representation based on a windowed Fourier transform (FT) is computed each time the window position is updated.
  • the RID module provides an improvement in resolution over the STFT based on the Wigner-Ville time-frequency distribution by presenting a result with reduced interference.
  • the WT module takes advantage of the fact that higher frequencies are better resolved in time while lower frequencies are better resolved in frequency.
  • Pacing parameter optimization module 430 determines one or more approximately optimal pacing parameters based on the one or more dyssynchrony parameters.
  • the approximately optimal pacing parameters provide for an approximately minimum degree of cardiac mechanical dyssynchrony.
  • Pacing controller 432 controls the delivery of pacing pulses to the heart from pacing circuit 434 using parameters provided by pacing parameter optimization module 430 for evaluating the parameters by their effects on the degree of cardiac mechamcal dyssynchrony.
  • the approximately optimal pacing parameters are determined by selecting parameters associated with the lowest degree of degree of cardiac mechanical dyssynchrony, as indicated by the one or more dyssynchrony parameters, from all the parameters evaluated.
  • pacing parameter optimization module 430 optimizes one or more pacing parameters by adjusting the one or more pacing parameters for an approximately optimal value of each of the one or more dyssynchrony parameters.
  • the approximately optimal value is a value associated with the minimum degree of cardiac mechamcal dyssynchrony obtained by the adjusting the one or more pacing parameters.
  • Pacing parameter optimization module 430 includes a parameter adjustment circuit to adjust the one or more pacing parameters.
  • the parameter adjustment circuit includes, but is not limited to, one or more of a pacing site selector, an atrioventricular delay (AVD) adjustment circuit, and an interventricular delay (lND) adjustment circuit.
  • the pacing site selector selects one or more pacing sites to which the pacing pulses are delivered.
  • the AVD adjustment circuit adjusts one or more AVDs at which ventricular pacing pulses are delivered.
  • the IVD adjustment circuit adjusts one or more IVDs at which ventricular pacing pulses are delivered.
  • pacing controller 432 controls the delivery of the pacing pulses from pacing circuit 434 using the adjusted parameters.
  • the optimization process includes repeated parameter adjustments and deliveries of pacing pulses using the adjusted parameters until an approximately minimum or otherwise satisfactory degree of cardiac mechanical dyssynchrony is reached.
  • pacing parameter optimization module 430 optimizes one or more pacing parameters by testing various combinations of values for the one or more pacing parameters for their effects on the degree of cardiac mechanical dyssynchrony.
  • Pacing parameter optimization module 430 includes a parameter generator to generate a plurality of pacing parameter value sets each including a value for each of the one or more pacing parameters.
  • the parameter generator includes, but is not limited to, one or more of a pacing site generator, an AVD generator, and an lND generator.
  • the pacing site generator generates a plurality of pacing sites or pacing site combinations to which the pacing pulses are delivered.
  • the AVD generator generates a plurality of AVDs at which ventricular pacing pulses are delivered.
  • the IVD generator generates a plurality of IVDs at which ventricular pacing pulses are delivered.
  • each of the pacing parameter value sets includes a unique combination of values for the tested parameters.
  • Pacing controller 432 controls the delivery of a plurality of pacing pulse sequences from pacing circuit 434. Each sequence includes a plurality of pacing pulses delivered using one of the pacing parameter value sets.
  • the optimization process includes identifying the pacing parameter value set that produces an approximately minimum or otherwise satisfactory degree of cardiac mechanical dyssynchrony.
  • pacing parameter optimization module 430 includes an optimal parameter selector to select an optimal parameter value set associated with the minimum degree of cardiac mechamcal dyssynchrony produced by pacing during the optimization process.
  • FIG. 5 is an illustration of one embodiment of a cardiac rhythm management (CRM) system 500 and portions of the environment in which system 500 is used.
  • CRM cardiac rhythm management
  • System 500 includes an implantable system 505, an external system 555, and a telemetry link 540 providing for communication between implantable system 505 and external system 555.
  • Implantable system 505 includes, among other things, implantable medical device 510 and lead system 508.
  • implantable medical device 510 is an implantable CRM device including one or more of a pacemaker, a cardioverter/defibrillator, a cardiac resynchronization therapy (CRT) device, a cardiac remodeling control therapy (RCT) device, a drug delivery device, and a biological therapy device.
  • implantable medical device 510 includes implantable sensors for sensing the signals used by cardiac mechanical dyssynchrony assessment module 410 and pacing parameter optimization module 430.
  • implantable medical device 510 and lead system 508 each include one or more of the implantable sensors. As shown in FIG. 5, implantable medical device 510 is implanted in a body 502. Lead system 508 provides connections between implantable medical device 510 and a heart 501. In various embodiments, lead system 508 includes leads for sensing physiological signals and delivering pacing pulses, cardioversion/defibrillation shocks, and/or pharmaceutical or other substances. In one embodiment, at least one implantable sensor is inco ⁇ orated into a lead of lead system 508 for placement in or about heart 501. In one embodiment, external system 555 is a patient management system including external device 550, network 560, and remote device 570.
  • External device 550 is within the vicinity of implantable medical device 510 and communicates with implantable medical device 510 bi-directionally via telemetry link 540.
  • Remote device 570 is in a remote location and communicates with external device 550 bi-directionally via network 560, thus allowing a user to monitor and treat a patient from a distant location.
  • external system includes a programmer communicating with implantable medical device 510 bi-directionally via telemetry link 540.
  • System 500 includes system 400 for optimizing pacing parameters based on the cardiac mechamcal dyssynchrony assessment.
  • system 500 also serves diagnostic and/or other therapeutic p poses by providing the user with heart sound signals indicative of cardiac mechanical dyssynchrony and/or other cardiovascular conditions.
  • implantable medical device 510 includes the entire system 400.
  • implantable medical device 510 includes portions of system 400, and external system 555 includes the remaining portions of system 400.
  • FIG. 6 is a block diagram illustrating one embodiment of a circuit of system 500, including implantable system 505, external system 555, and telemetry link 540 wirelessly coupling the two systems.
  • Implantable system 505 includes lead system 508, heart sound sensor 402, respiratory sensor 404, and implantable medical device 510.
  • Lead system 508 includes pacing leads each having at least one electrode to be placed in a heart chamber. Each pacing lead allows delivery of pacing pulses to, and sensing of cardiac electrical activity from, a cardiac location where the electrode is placed.
  • lead system 508 includes one or more atrial pacing leads and one or more ventricular pacing leads.
  • the one or more atrial pacing leads include at least one RA pacing lead.
  • the one or more ventricular pacing leads include one or more RV pacing lead and/or one or more LV pacmg leads.
  • heart sound sensor 402 includes one sensor housed in implantable medical device 510 to sense heart sound signal 302G.
  • heart sound sensor 402 includes one intracardiac sensor inco ⁇ orated into a pacing lead of lead system 508 for placement within a heart chamber to sense heart sound signal 302G.
  • heart sound sensor 402 includes one intracardiac sensor inco ⁇ orated into an RV pacing lead to sense heart sound signal 302R and another intracardiac sensor or epicardial sensor inco ⁇ orated into an LV pacing lead to sense heart sound signal 302L.
  • respiratory sensor 404 is housed in implantable medical device 510.
  • respiratory sensor 404 is inco ⁇ orated into a pacing lead of lead system 508 for placement within a heart chamber.
  • Implantable medical device 510 includes pacing circuit 434, a sensing circuit 603, an implant controller 636, and an implant telemetry module 642.
  • Pacing circuit 434 produces pacing pulses and delivers the pacing pulses to the heart through lead system 508.
  • Sensing circuit 603 senses electrograms indicative of cardiac electrical activities.
  • Implant controller 636 includes at least pacing controller 432, heart sound signal processor 403, and respiratory signal processor 405.
  • Pacing controller 432 controls pacing circuit 434 by executing a selected pacing algorithm using at least the cardiac activities sensed by sensing circuit 603 and pacing parameters programmed into implant controller 636 as inputs.
  • External system 555 includes an external telemetry module 644 and an external controller 652.
  • External controller 652 includes cardiac mechanical dyssynchrony assessment module 410 and pacing parameter optimization module 430.
  • remote device 570 includes cardiac mechamcal dyssynchrony assessment module 410 and pacing parameter optimization module 430. This allows long-term therapy optimization performed by the user, or by system 500 automatically, in a location away from the patient's presence.
  • system 500 provides for therapy optimization on a continuous basis.
  • system 500 provides for therapy optimization on a predetennined schedule, such as on a periodic basis.
  • system 500 provides for therapy optimization in response to a change of patient condition detected by or through implantable system 505.
  • system 500 provides for therapy optimization in response to a command entered by the user.
  • the therapy optimization results in one or more optimal pacing parameter values to be programmed into implant controller 636.
  • Implant telemetry module 642 and external telemetry module 644 support telemetry link 540.
  • Telemetry link 540 is a wireless bidirectional data transmission link.
  • telemetry link 540 is an inductive couple formed when two coils — one connected to implant telemetry module 642 and the other coimected to external telemetry module 644 — are placed near each other. In this embodiment, the patient or the user places the coil connected to external device 550 on body 502 over implantable medical device 510.
  • telemetry link 540 is a far-field radio-frequency telemetry link allowing implantable medical device 510 and external device 550 to communicate over a telemetry range that is at least ten feet.
  • implant telemetry module 642 transmits the heart sound and respiratory signals acquired by implantable system 505, and external telemetry module 644 receives these signals.
  • FIG. 7 is a flow chart illustrating one embodiment of a method for optimizing pacing parameters based on the cardiac mechamcal dyssynchrony assessment. In one embodiment, the method is performed by system 400.
  • One or more heart sound signals indicative of at least SI and S2 are sensed at 700.
  • the one or more heart sound signals include one or more acceleration signals indicative of the heart's mechanical vibrations.
  • the one or more heart sound signals include one or more audio signals originated from the heart.
  • heart sound signal 302G is sensed at 700.
  • heart sound signals 302R and 302L are sensed at 700.
  • both heart sound signal 302G and heart sound signals 302R and 302L are sensed at 700.
  • a respiratory signal indicative of respiratory cycles each including an inspiratory phase and expiratory phase is also sensed.
  • the respiratory signal includes an impedance signal indicative minute ventilation.
  • the one or more heart sound signals are processed at 710. The process includes envelope-detecting the one or more heart sound signals by rectification and low-pass filtering.
  • each envelope-detected heart sound signal is ensemble averaged to improve its signal-to-noise ratio.
  • the respiratory signal is also processed at 710. The process includes detection of expiratory phases. Cardiac mechanical dyssynchrony is assessed based on the one or more heart sound signals at 720. The one or more heart sound signals are received at 722. In one embodiment, the respiratory signal is also received at 722. In one embodiment, only S2 G , and/or S2 RV and S2 L V, that occur during the expiratory phase of the respiratory cycle are used for the assessment of cardiac mechamcal dyssynchrony. SI and S2 are detected from the one or more heart sound signals at 724. In one embodiment, S1G and S2Q are detected from heart sound signal 302G.
  • SIRV and S2R V are detected from heart sound signal 302R
  • SILV and S2LV are detected from heart sound signal 302L.
  • One or more dyssynchrony parameters each indicative of the degree of cardiac mechanical dyssynchrony are produced based on mo ⁇ hological features of, or related to, SI and S2 at 726.
  • an automated cardiac mechanical dyssynchrony algorithm is executed to detect mo ⁇ hological features of detected SI and S2, make measurements related to the mo ⁇ hological features, and produce the one or more dyssynchrony parameters based on results of the measurements at 726.
  • the mo ⁇ hological features indicate cardiac valve closure delays.
  • a first dyssynchrony parameter related to SI and a second dyssynchrony parameter related to S2 are produced at 726.
  • the production of the dyssynchrony parameters includes measuring one or more parameters associated with the mo ⁇ hological features.
  • SI width 310 and S2 width 312 are measured from heart sound signal 302G.
  • SI delay 314 and S2 delay 316 are measured from heart sound signal 302G.
  • SI delay 314 is measured as the time interval between the peak of S1Q associated with mitral valve closure and the peak of S IQ associated with tricuspid valve closure.
  • S2 delay 316 is measured as the time interval between the peak S2Q associated with aortic valve closure and the peak S2 G associated with pulmonary valve closure.
  • SI delay 314 and S2 delay 316 are measured from heart sound signals 302R and 302L.
  • SI delay 314 is measured as the time interval between SI R V and SIL V - S2 delay 316 is measured as the time interval between S2RV and S2 L V-
  • at least one time-frequency representation for each of the one or more heart sound signals is produced.
  • the time-frequency representation is produced by, for example, performing one or more of STFT, RID, and WT.
  • One or more dyssynchrony parameters are produced each based on at least one feature in the time-frequency representation.
  • a parameter is produced to indicate puhnonary artery pressure based on at least one feature in the time-frequency representation.
  • One or more pacing parameters are optimized at 730, based on the one or more dyssynchrony parameters produced at 726.
  • the one or more parameters are optimized when the one or more dyssynchrony parameters indicate an approximately minimum degree of cardiac mechanical dyssynchrony.
  • the one or more pacing parameters are optimized based on at least one dyssynchrony parameter produced based on S2 measurements. The optimization is to minimize the time interval between pulmonary valve closure and aortic valve closure.
  • the one or more pacing parameters are optimized based on at least one dyssynchrony parameter produced based on SI measurements. The optimization is to minimize the time interval between tricuspid valve closure and mitral valve closure.
  • the one or more pacing parameters are optimized based on dyssynchrony parameters produced based on both S 1 and S2 measurements.
  • the nuiiimization of the time interval between pulmonary valve closure and aortic valve closure has a higher priority.
  • the one or more pacing parameters are adjusted for an approximately optimal value of each of the one or more dyssynchrony parameters.
  • the approximately optimal value is a value associated with an approximately minimum degree of cardiac mechanical dyssynchrony obtained by adjusting the one or more pacing parameters.
  • Adjusting the one or more pacing parameters includes, but is not limited to, selecting one or more pacing sites to which the pacing pulses are delivered, adjusting one or more AVDs at which ventricular pacing pulses are delivered, and adjusting one or more IVDs at which ventricular pacing pulses are delivered. After each parameter adjustment, a plurality of pacing pulses is delivered to the heart using the one or more adjusted pacing parameters.
  • the optimization process includes repeated parameter adjustments and delivery of pacing pulses using the adjusted parameters until an approximately minimum or otherwise satisfactory degree of cardiac mechanical dyssynchrony is reached.
  • the one or more pacing parameters are optimized by testing the effects of various combinations of values of the one or more pacing parameters on the one or more dyssynchrony parameters.
  • a plurality of pacing parameter value sets is generated.
  • Each pacing parameter value set includes a value for each of the one or more pacing parameters.
  • Generating the plurality of pacing parameter value sets includes, but is not limited to, generating a plurality of pacing sites or pacing site combinations to which pacing pulses are delivered, generating a plurality of AVDs at which ventricular pacing pulses are delivered, and generating a plurality of IVDs at which ventricular pacing pulses are delivered.
  • a plurality of pacing pulse sequences are delivered.
  • Each sequence includes a plurality of pacing pulses delivered using one pacing parameter value set of the plurality of pacing parameter value sets.
  • An optimal parameter value set is selected from the plurality of pacing parameter value sets.
  • the optimal pacing parameter value set is associated with an approximately optimal value of at least one of the one or more dyssynchrony parameters.
  • the approximately optimal value is associated with a minimum degree of cardiac mechanical dyssynchrony obtained by pacing with the plurality of pacing parameter sets.

Abstract

A cardiac rhythm management system provides for assessment of cardiac mechanical dyssynchrony based on heart sound morphology and optimization of pacing parameters based on the effect of pacing on the cardiac mechanical dyssynchrony assessment. A degree of cardiac mechanical dyssynchrony is measured by the time delay between tricuspid valve closure and mitral valve closure and/or the time delay between pulmonary valve closure and aortic valve closure. A cardiac resynchronization therapy is optimized by determining therapy parameters to provide an approximately minimum degree of cardiac mechanical dyssynchrony by cardiac pacing.

Description

METHOD AND APPARATUS FOR INDIVIDUAL INTRAVENTRICULAR DELAY OPTIMIZATION
Claim of Priority Benefit of priority is hereby claimed to U.S. Patent Application Serial
Number 10/865,498, filed on June 10 2004, which application is herein incorporated by reference.
Cross-Reference to Related Applications This application is related to co-pending, commonly assigned, U.S.
Patent Application Serial No. 10/334,694, entitled "METHOD AND APPARATUS FOR MONITORING OF DIASTOLIC HEMODYNAMICS," filed December 30, 2002, and U.S. Patent Application Serial No. 10/307,896, "PHONOCARDIOGRAPHIC IMAGE-BASED ATRIOVENTRICULAR DELAY OPTIMIZATION," filed December 2, 2002, which are hereby incorporated by reference in their entirety.
Field of the Invention This document generally relates to cardiac rhythm management (CRM) systems and particularly, but not by way of limitation, to such systems providing for optimization of cardiac therapy using heart sounds.
Background The heart is the center of a person's circulatory system. It includes a complex electro-mechanical system performing two major pumping functions. The heart includes four chambers: right atrium (RA), right ventricle (RV), left atrium (LA), and left ventricle (LV). The RA draws deoxygenated blood from organs of the body and injects it into the RV through the tricuspid valve. The RV pumps the deoxygenated blood to the lungs through the pulmonary valve. The blood gets oxygenated in the lungs. The LA draws oxygenated blood from the lungs and injects it into the LV through the mitral valve. The LV pumps the oxygenated blood to the organs of the body, through the aortic valve, to provide the organs with their metabolic needs for oxygen. These mechanical pumping functions are accomplished by contractions of the myocardium (heart muscles). In a normal heart, the siiioatrial (SA) node, the heart's natural pacemaker, generates electrical impulses, called action potentials, that propagate through an electrical conduction system to various regions of the heart to excite myocardial tissues in these regions. Coordinated delays in the propagations of the action potentials in a normal electrical conduction system cause the muscles in various regions of the heart to contract in mechanical synchrony such that the pumping functions are performed efficiently. The normal pumping functions of the heart, indicated by the normal hemodynamic performance, require a normal electrical system to generate the action potentials and deliver them to designated portions of the myocardium with proper timing, a normal myocardium capable of contracting with sufficient strength, and a normal electro-mechanical association such that all regions of the heart are excitable by the action potentials. A blocked or otherwise abnormal electrical conduction and/or deteriorated myocardial tissue cause dysynchronous contraction of the heart, resulting in poor hemodynamic performance, including a diminished blood supply to the heart and the rest of the body. The condition where the heart fails to pump enough blood to meet the body's metabolic needs is known as heart failure. Because the pumping functions are mechanical functions, the hemodynamic performance is ultimately determined by the mechanical synchrony of the heart. For this and other reasons, there is a need for a direct assessment of cardiac mechanical dyssynchrony. The assessment serves as a direct measure of efficacy for a cardiac therapy restoring the cardiac mechanical synchrony.
Summary A cardiac rhythm management (CRM) system provides for assessment of cardiac mechanical dyssynchrony based on heart sound morphology and optimization of pacing parameters based on the effect of pacing on the cardiac mechanical dyssynchrony assessment. A degree of cardiac mechanical dyssynchrony is measured by the time delay between tricuspid valve closure and mitral valve closure and or the time delay between pulmonary valve closure and aortic valve closure. A cardiac ^synchronization therapy is optimized by determining therapy parameters to provide an approximately minimum degree of cardiac mechanical dyssynchrony by cardiac pacing. In one embodiment, a system for analyzing a heart includes a heart sound input, a heart sound detector, and a computer-based heart sound morphology analyzer. The heart sound input receives one or more signals indicative of heart sounds. The heart sound detector detects heart sounds of at least one predeteπnined type. The computer-based heart sound morphology analyzer produces at least one dyssynchrony parameter indicative of a degree of cardiac mechanical dyssynchrony based on measurements of the detected heart sounds. The heart sound morphology analyzer includes a heart sound measurement module to measure one or more parameters each based on at least one morphological feature of the detected heart sounds. The morphological feature indicates a time interval between closures of a first cardiac valve and a second cardiac valve of the heart in one cardiac cycle. In one embodiment, a system for analyzing a heart includes an implantable system and an external system communicating with the implantable system. The implantable system includes one or more implantable heart sound sensors and an implantable medical device. The one or more implantable heart sound sensors sense one or more heart sound signals each indicative of heart sounds. The implantable medical device includes an implant controller to process the one or more heart sound signals and an implant telemetry module to transmit the one or more heart sound signals to the external system. The external system includes an external telemetry module to receive the one or more heart sound signals and an external controller to process the one or more heart sound signals. The external controller includes a heart sound morphology analyzer to produce at least one dyssynchrony parameter indicative of a degree of cardiac mechanical dyssynchrony. The heart sound morphology analyzer includes a heart sound measurement module to measure one or more parameters each based on at least one morpho logical feature of heart sounds of at least one predetermined type. The morphological feature indicates a time interval between closures of a first cardiac valve and a second cardiac valve of a heart in one cardiac cycle. In one embodiment, a method for operating a cardiac pacemaker is provided. One or more heart sound signals indicative of heart sounds are received. Heart sounds of at least one predetermined type are detected. One or more dyssynchrony parameters each indicative of a degree of cardiac mechanical dyssynchrony are produced based on at least one morphological feature of the detected heart sounds by executing an automated cardiac mechanical dyssynchrony algorithm. One or more pacing parameters for minimizing the degree of cardiac mechanical dyssynchrony are detennined based on the one or more dyssynchrony parameters. This Summary is an overview of some of the teachings of the present application and not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details about the present subject matter are found in the detailed description and appended claims. Other aspects of the invention will be apparent to persons skilled in the art upon reading and understanding the following detailed description and viewing the drawings that form a part thereof, each of which are not to be taken in a limiting sense. The scope of the present invention is defined by the appended claims and their equivalents.
Brief Description of the Drawings In the drawings, which are for illustrative purposes only and not necessarily drawn to scale, like numerals describe similar components throughout the several views. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document. FIG. 1 is a graph illustrating a sensed heart sound signal before and after envelope detection. FIG. 2 is a graph illustrating heart sound signals indicative of cardiac mechanical synchrony sensed by various heart sound sensors. FIG. 3 is a graph illustrating heart sound signals indicative of cardiac mechanical dyssynchrony sensed by various heart sound sensors. FIG. 4 is a block diagram illustrating one embodiment of a system for optimizing pacing parameters based on a cardiac mechanical dyssynchrony assessment. FIG. 5 is an illustration of one embodiment of a CRM system and portions of the environment in which the CRM system is used. FIG. 6 is a block diagram illustrating one embodiment of a circuit of the CRM system. FIG. 7 is a flow chart illustrating one embodiment of a method for optimizing pacing parameters based on the cardiac mechanical dyssynchrony assessment.
Detailed Description In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the spirit and scope of the present invention. The following detailed description provides examples, and the scope of the present invention is defined by the appended claims and their equivalents. It should be noted that references to "an", "one", or "various" embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment. This document discusses, among other things, a method and system for optimizing therapies based on mechanical performance of the heart as indicated by heart sounds. Heart sounds, or generally energies resulted from the heart's mechanical vibrations, indicate the heart's mechamcal activities, including the openings and closures of the tricuspid, pulmonary, mitral, and aortic valves.
Because hemodynamic performance is ultimately determined by the mechamcal synchrony of the heart, heart sounds provide a direct measure of efficacy for a therapy intended to restore the heart's ability to contract in synchrony. Throughout this document, "heart sound" includes audible and inaudible mechanical vibrations caused by cardiac mechamcal activities that can be sensed with an accelerometer. SI generally refers to a heart sound type known as the "first heart sound," or as one or more occurrences or instances of the first heart sound, depending on the context. S2 generally refers to a heart sound type known as the "second heart sound," or as one or more occurrences or instances of the second heart sound, depending on the context. A "user" includes a physician or other caregiver who examines and/or treats a patient using one or more of the methods and apparatuses reported in the present document. FIG. 1 is a graph illustrating a sensed heart sound signal 100 and a processed heart sound signal 102 over one cardiac cycle. Both signals 100 and 102 indicate SI and S2. Sensed heart sound signal 100 represents an output of a heart sound sensor such as an accelerometer sensing the heart's mechanical vibrations or a microphone sensing audible sound originated from the heart. The signal is conditioned by at least envelope detection to produce heart sound signal 102. In the system and method descriptions below, a "heart sound signal" refers to either a heart sound signal as an output of a heart sound sensor, such as illustrated by signal 100, or a heart sound signal that has been envelope detected, such as illustrated by signal 102. Each cardiac cycle includes a diastolic phase, during which blood fills the RV through the tricuspid valve and the LV through mitral valve, and a systolic phase, during which the blood are ejected from the RV through the pulmonary valve and the LV through the aortic valve. SI is known to originate from, among other things, the mechanical vibrations associated with tricuspid valve closure and mitral valve closure, which start the diastolic phase. S2 is known to originate from, among other things, the mechanical vibrations associated with pulmonary valve closure and aortic valve closure, which start the systolic phase. FIG. 2 is a graph illustrating heart sound signals indicative of cardiac mechanical synchrony sensed by various heart sound sensors over a cardiac cycle. A "global" heart sound signal 202G is sensed by a single heart sound sensor sensing heart sounds originated from the entire heart. Heart sound signal 202G indicates SIG (global SI) and S2G (global S2) for heart that contracts synchronously. S 1G is morphologically characterized by a single peak and an S 1 width 210 that falls within the normal SI width range. S2Q is morphologically characterized by a single peak and an S2 width 212 that falls within the normal S2 width range. "Regional" heart sound signals 202R and 202L are sensed simultaneously using two sensors each primarily sensing heart sounds originated from one portion of the heart, such as the right portion or the left portion. In one embodiment, heart sound signal 202R is sensed by a heart sound sensor placed within the RV, and heart sound signal 202L is sensed by a heart sound sensor placed within the LV. RV heart sound signal 202R indicates S1RV (SI sensed in the RV) and S2RV (S2 sensed in the RV). SIRV indicates tricuspid valve closure. S2Rv indicates pulmonary valve closure. LV heart sound signal 202L indicates SlLv (SI sensed in the LV) and S2Lv (S2 sensed in the LV). S1LV indicates mitral valve closure. S2LV indicates aortic valve closure. In a heart that contracts in synchrony, tricuspid valve closure (SIRV) and mitral valve closure (SILV) occur substantially simultaneously. The sounds of tricuspid valve closure and mitral valve closure substantially overlap, producing the normal S1G- Pulmonary valve closure (S2RV) and aortic valve closure (S2RV) occur substantially simultaneously. The sounds of pulmonary valve closure and aortic valve closure substantially overlap, producing the normal S2G. FIG. 3 is a graph illustrating heart sound signals indicative of cardiac mechanical dyssynchrony sensed by various heart sound sensors over a cardiac cycle. A "global" heard sound signal 302G is sensed by a single heart sound sensor sensing heart sounds originated from the entire heart. "Regional" heart sound signals 302R and 302L are sensed simultaneously using two sensors each primarily sensing heart sounds originated from one portion of the heart. Heart sound signal 302G corresponds to heart sound signal 202G, heart sound signal 302R corresponds to heart sound signal 202R, and heart sound signal 302L corresponds to heart sound signal 202L. While signals 202G, 202R, and 202L illustrates heart sound signals indicative cardiac synchrony, signals 302G, 302R, and 302L illustrates heart sound signals indicative cardiac dyssynchrony. When the cardiac muscles in various regions of the heart fail to contract in synchrony, i.e., when cardiac mechanical dyssynchrony occurs, relative timing between the valve closures deviates from their normal timing. A delay 314 between tricuspid valve closure (S IRV) and mitral valve closure (S ILV) indicates that the tricuspid valve and the mitral valve no longer close substantially simultaneously. The delay results in a double peaked S 1G, and/or an abnormally large SI width 310 associated with S1G. A delay 316 between pulmonary valve closure (S2RV) and aortic valve closure (S2LV) indicates that the pulmonary valve and the aortic valve no longer close substantially simultaneously. The delay results in a double peaked S2G, and/or an abnormally large 82 width 312 associated with S2Q. Depends on individual conditions, a heart that fails to contract in synchrony may be indicated by one or more of delay 314 and delay 316 and/or one or more of SI width 310 and S2 width 312. It is to be understood that the relative timing between SIRV and SILV and the relative timing between S2R and S2Lv as shown in FIG. 3 represents an example for illustrative purpose only. FIG. 3 shows exemplary heart sound signals of a patient suffering left bundle branch block (LBBB), in which SIRV leads SlLv in time, and S2RV leads S2LV in time. However, the system and method discussed below are generally applicable to cardiac mechanical dyssynchrony indicated by any one or more of delay 314, delay 316, an abnormally long SI width 310, and an abnormally long S2 width 312. An effective treatment to resynchronize the heart shortens or eliminates either or both delays 314 and 316 and restores both widths 310 and 312 to their normal values. In other words, the goals of the treatment include (i) merging the two peaks of S1Q, and merging the two peaks of S2G, or (ii) realigning SIRV and SILV, and realigning S2RV and S2LV- In case the goal with respect to SI and the goal with respect to S2 cannot be both met, higher priority is given to the goal of (i) merging the two peaks of S2G, or (ii) realigning S2RV and S2LV- One example of such treatment is the application of cardiac resynchronization therapy (CRT), which resynchronizes the contractions of the heart, particularly the ventricles, by delivering ventricular pacing pulses using proper timing. The extent to which a therapy restores cardiac synchrony is indicated by the extent to which delay 314 or 316 are reduced, or by the extent to which width 310 and 312 returned to their normal values. In system and method descriptions below, heart sound signals 302G,
302R, and 302L, and heart sounds S 1G, S2Q, SIRV, S2RV, SILV, and S2RV are used for illustrative, but not restrictive, purposes. Heart sound signal 302G generally includes a "global" heart sound sensed by a single sensor and indicative of heart sounds originating from anywhere in the heart. Heart sound signals 302R and 302L include two heart sound signals simultaneously by two sensors. Heart sound signal 302R generally includes a "regional" heart sound indicative of primarily heart sounds originating from the right side of the heart, sensed by such as a sensor placed in the RV. Heart sound signal 302L generally includes another "regional" heart sound indicative of primarily heart sounds originating from the left side of the heart, sensed by such as a sensor placed in the LV. S1G generally includes a heart sound resulted from a combination of tricuspid valve closure and mitral valve closure. S2G generally includes a heart sound resulted from a combination of pulmonary valve closure and aortic valve closure. S IRV generally includes a heart sound resulted from tricuspid valve closure. S2RV generally includes a heart sound resulted from pulmonary valve closure. SILV generally includes a heart sound resulted from mitral valve closure. S2LV generally includes a heart sound resulted from aortic valve closure. SI generally refers to the heart sound type known as the "first heart sound," or as one or more occurrences of the "first heart sounds," including S1G, SIRV, and SILV- S2 generally refers to a heart sound type known as the "second heart sound," or as one or more occurrences of the "second heart sounds," including S2G, S2RV, and S2RV. FIG. 4 is a block diagram illustrating one embodiment of a system 400 for optimizing pacing parameters based on a cardiac mechamcal dyssynchrony assessment. System 400 includes a heart sound sensor 402, a heart sound signal processor 403, a respiratory sensor 404, a respiratory signal processor 405, a cardiac mechanical dyssynchrony assessment module 410, a pacing parameter optimization module 430, a pacing controller 432, and a pacing circuit 434. In one embodiment, portions of system 400 are implemented as a computer-based system. Heart sound sensor 402 includes one or more sensors each sense a signal indicative of heart sounds. Examples of the one or more sensors include accelerometers and microphones. In one embodiment, heart sound sensor 402 includes a single heart sound sensor to sense a heart sound signal 302G. In one specific embodiment, the single heart sound sensor is placed external to the heart. In another specific embodiment, the single heart sound sensor is placed within a heart chamber. In another embodiment, heart sound sensor 402 is a sensor system including a plurality of heart sound sensors each sensing a signal indicative of heart sounds originating from a particular portion of the heart. In one specific embodiment, the plurality of heart sound sensors include an Ry heart sound sensor to sense heart sound signal 302R and an LV heart sound sensor to sense heart sound signal 302L. In one specific embodiment, the RV heart sound sensor is an intracardiac heart sound sensor for placement in the RV to sense a heart sound signal indicative of at least tricuspid valve closure and pulmonary valve closure, and the LV heart sound sensor is another intracardiac heart sound sensor for placement in the LV to sense a heart sound signal indicative of at least mitral valve closure and aortic valve closure. In another specific embodiment, the RV heart sound sensor is the intracardiac heart sound sensor for placement in the RV to sense the heart sound signal indicative of at least tricuspid valve closure and pulmonary valve closure, and the LV heart sound sensor is an epicardial heart sound sensor for placement on the epicardial wall over the LV to sense a heart sound signal indicative of at least mitral valve closure and aortic valve closure. Heart sound signal processor 403 conditions the one or more heart sound signals sensed by heart sound sensor 402. Heart sound signal processor 403 includes an envelope detector to produce heart sound signal 302G and/or heart sound signals 302R and 302L. In one embodiment, heart sound signal processor 403 further includes an ensemble averaging circuit to improve a signal-to-noise ratio of each of the one or more heart sound signals by ensemble averaging. Respiratory sensor 404 senses a respiratory signal indicative of respiratory cycles each including an inspiratory phase and expiratory phase. In one embodiment, respiratory sensor 404 includes an accelerometer sensing an acceleration signal indicative of inspiration and expiration. In another embodiment, respiratory sensor 404 includes a minute ventilation sensor. In one specific embodiment, the minute ventilation sensor is an implantable impedance sensor sensing a thoracic impedance indicative of minute ventilation. Respiration signal processor 405 conditions the respiratoiy signal for use by cardiac mechanical dyssynchrony assessment module 410. In one embodiment, respiration signal processor 405 includes an expiration detector to detect and indicate each expiratory phase of the respiratory cycle. Cardiac mechanical dyssynchrony assessment module 410 produces one or more dyssynchrony parameters each indicative of a degree of cardiac mechanical dyssynchrony based on at least the one or more heart sound signals sensed by heart sound sensor 402 and preprocessed by heart sound signal processor 403. Cardiac mechanical dyssynchrony assessment module 410 includes a heart sound input 412, a respiratory signal input 413, a heart sound detector 414, and a heart sound morphology analyzer 420. In one embodiment, cardiac mechanical dyssynchrony assessment module 410 is implemented as a computer-based system. In one specific embodiment, cardiac mechamcal dyssynchrony assessment module 410 produces the one or more dyssynchrony parameters by executing an automated cardiac mechanical dyssynchrony algorithm using at least the one or more heard sound signals and/or detected SI and S2 as input. Heart sound input 412 receives the one or more heart sound signals, such as heart sound signal 302G and/or heart sound signals 302R and 302L. Respiratory signal input 413 receive the respiratory signal indicative of which occurrences of S2G and/or S2RV and S2 V are detected during an expiratory phase. Heart sound detector 414 detects heart sounds from the one or more heart sound signals. Heart sound detector 414 includes at least an SI detector 416 and an S2 detector 418. In one embodiment, SI detector 416 detects S1G, and S2 detector 418 detects S2G, both from heart sound signal 302G. In another embodiment, SI detector 416 detects SIRV fr m heart sound signal 302R and SILV from heart sound signal 302L, and S2 detector 418 detects S2RV from heart sound signal 302R and S2LV from heart sound signal 302L. Heart sound morphology analyzer 420 produces one or more dyssynchrony parameters. In one embodiment, heart sound morphology analyzer 420 is a computer-based analyzer that produces the one or more dyssynchrony parameters by executing the automated cardiac mechanical dyssynchrony algorithm. The automated cardiac mechanical dyssynchrony algorithm is designed to detect morphological features of detected SI and S2, make measurements related to the morphological features, and produce the one or more dyssynchrony parameters based on results of the measurements, as described below. Heart sound morphology analyzer 420 includes at least an SI moφhology analyzer 422 to produce a dyssynchrony parameter related to S1G (or S IRV and SILV) and an S2 moφhology analyzer 426 to produce another dyssynchrony parameter related to S2G (or S2RV and S2LV)- In one embodiment, S2 moφhology analyzer 426 to produce the dyssynchrony parameter related to S2G (or S2RV and S2LV) based on only on S2G (or S2RV and S2LV) detected during an expiratory phase of the respiratory cycle. Heart sound moφhology analyzer 420 includes one or more heart sound measurement modules to measure parameters associated with the moφhological features of the one or more heart sounds. SI moφhology analyzer 422 includes an SI measurement module 424. S2 moφhology analyzer 426 includes an S2 width measurement module 428. In one embodiment, each heart sound measurement module includes a heart sound width measurement module to measure widths of the heart sounds. SI measurement module 424 includes an SI width measurement module to measure SI width 310 (the width of S1G). S2 measurement module 428 includes an S2 width measurement module to measure S2 width 312 (the width of S2G). In another embodiment, each heart sound measurement module includes a heart sound delay measurement modules to measure delays in cardiac valve closure as indicated by heart sounds in a single heart sound signal such as heart sound signal 302G. Each heart sound delay measurement module includes a peak detector and a timer. The peak detector detects peaks within a heart sound each indicating one valve closure. If two peaks are detected within the heart sound, the timer measures the delay as the time interval between the two peaks. In this embodiment, SI measurement module 424 includes an SI delay measurement measure to measure SI delay 314 as a time interval between two peaks detected within S1G- S2 measurement module 428 includes an S2 delay measurement measure to measure S2 delay 316 as a time interval between two peaks detected within S2G. In one embodiment, an imaging technique, such as tissue Doppler imaging (TDI), echocardiography, or magnetic resonance imaging (MRI), is applied to differentiate between the two peaks of S1G- This provides for identification of the peak associated with tricuspid valve closure and the peak associated with mitral valve closure in S1G- Normally, the puhnonary valve closure is delayed during an inspiratory phase. In one embodiment, this fact is utilized to differentiate between the two peaks of S2Q. This provides for identification of the peak associated with pulmonary valve closure and the peak associated with aortic valve closure in S2G- In one embodiment, each heart sound measurement modules of moφhology analyzer 420 is calibrated on a periodic basis or as needed using these peak identification techniques. In another embodiment, each heart sound measurement module includes a heart sound delay measurement modules to measure delays in cardiac valve closure as indicated by heart sounds in two heart sound signals such as heart sound signals 302R and 302L. Each heart sound delay measurement module includes a timer to measure the delay being a time interval between a heart sound detected in one heart sound signal and the heart sound detected in another heart sound signal. In this embodiment, SI measurement module 424 includes an S 1 delay measurement module to measure S 1 delay 314 as the time interval between SIRV and SILV- S2 measurement module 428 includes an S2 delay measurement module to measure S2 delay 316 as the time interval between S2RV and S2LV- In another embodiment, heart sound moφhology analyzer 420 includes a heart sound time-frequency analyzer to produce at least one time-frequency representation for each of the one or more heart sound signals and produce the one or more dyssynchrony parameters each associated with at least one feature of the one time-frequency representation. In one embodiment, the heart sound time-frequency analyzer further produces a parameter indicative of pulmonary artery pressure based on at least one feature of the time-frequency representation. The heart sound time-frequency analyzer includes, by way of example, and not by way of limitation, one or more of a short-time Fourier transform (STFT) module, a reduced interference (RID) module, and a wavelet transform (WT) module. The STFT module produces a time versus frequency representation of the signal by applying a sliding window to data representing the one or more heart sound signals. A spectral representation based on a windowed Fourier transform (FT) is computed each time the window position is updated. The RID module provides an improvement in resolution over the STFT based on the Wigner-Ville time-frequency distribution by presenting a result with reduced interference. The WT module takes advantage of the fact that higher frequencies are better resolved in time while lower frequencies are better resolved in frequency. This processing involves recursively filtering the data representing the one or more heart sound signals at different scales with sets of high-pass and low-pass filters. Pacing parameter optimization module 430 determines one or more approximately optimal pacing parameters based on the one or more dyssynchrony parameters. The approximately optimal pacing parameters provide for an approximately minimum degree of cardiac mechanical dyssynchrony. Pacing controller 432 controls the delivery of pacing pulses to the heart from pacing circuit 434 using parameters provided by pacing parameter optimization module 430 for evaluating the parameters by their effects on the degree of cardiac mechamcal dyssynchrony. The approximately optimal pacing parameters are determined by selecting parameters associated with the lowest degree of degree of cardiac mechanical dyssynchrony, as indicated by the one or more dyssynchrony parameters, from all the parameters evaluated. In one embodiment, pacing parameter optimization module 430 optimizes one or more pacing parameters by adjusting the one or more pacing parameters for an approximately optimal value of each of the one or more dyssynchrony parameters. The approximately optimal value is a value associated with the minimum degree of cardiac mechamcal dyssynchrony obtained by the adjusting the one or more pacing parameters. Pacing parameter optimization module 430 includes a parameter adjustment circuit to adjust the one or more pacing parameters. The parameter adjustment circuit includes, but is not limited to, one or more of a pacing site selector, an atrioventricular delay (AVD) adjustment circuit, and an interventricular delay (lND) adjustment circuit. The pacing site selector selects one or more pacing sites to which the pacing pulses are delivered. The AVD adjustment circuit adjusts one or more AVDs at which ventricular pacing pulses are delivered. The IVD adjustment circuit adjusts one or more IVDs at which ventricular pacing pulses are delivered. After each adjustment of any one or more of the pacing sites, AVDs, and IVDs, pacing controller 432 controls the delivery of the pacing pulses from pacing circuit 434 using the adjusted parameters. The optimization process includes repeated parameter adjustments and deliveries of pacing pulses using the adjusted parameters until an approximately minimum or otherwise satisfactory degree of cardiac mechanical dyssynchrony is reached. In another embodiment, pacing parameter optimization module 430 optimizes one or more pacing parameters by testing various combinations of values for the one or more pacing parameters for their effects on the degree of cardiac mechanical dyssynchrony. Pacing parameter optimization module 430 includes a parameter generator to generate a plurality of pacing parameter value sets each including a value for each of the one or more pacing parameters. The parameter generator includes, but is not limited to, one or more of a pacing site generator, an AVD generator, and an lND generator. The pacing site generator generates a plurality of pacing sites or pacing site combinations to which the pacing pulses are delivered. The AVD generator generates a plurality of AVDs at which ventricular pacing pulses are delivered. The IVD generator generates a plurality of IVDs at which ventricular pacing pulses are delivered. In one embodiment where more than one pacing parameter is being tested, each of the pacing parameter value sets includes a unique combination of values for the tested parameters. Pacing controller 432 controls the delivery of a plurality of pacing pulse sequences from pacing circuit 434. Each sequence includes a plurality of pacing pulses delivered using one of the pacing parameter value sets. The optimization process includes identifying the pacing parameter value set that produces an approximately minimum or otherwise satisfactory degree of cardiac mechanical dyssynchrony. In one embodiment, pacing parameter optimization module 430 includes an optimal parameter selector to select an optimal parameter value set associated with the minimum degree of cardiac mechamcal dyssynchrony produced by pacing during the optimization process. It is to be understood that while optimization of pacing parameters, and particularly the pacing sites, AVDs, and IVDs are discussed as examples, the idea of adjusting or optimizing a therapy using a measure of cardiac mechanical dyssynchrony is not limited to the optimization of pacing therapy. The basic concept of adjusting or optimizing a therapy by determining therapy parameters providing for a minimum degree of cardiac mechamcal dyssynchrony generally applies to the optimization of other pacing parameters and other therapies including, but not being limited to, other electrical therapies, physical therapies, chemical therapies, and biological therapies. FIG. 5 is an illustration of one embodiment of a cardiac rhythm management (CRM) system 500 and portions of the environment in which system 500 is used. System 500 includes an implantable system 505, an external system 555, and a telemetry link 540 providing for communication between implantable system 505 and external system 555. Implantable system 505 includes, among other things, implantable medical device 510 and lead system 508. In various embodiments, implantable medical device 510 is an implantable CRM device including one or more of a pacemaker, a cardioverter/defibrillator, a cardiac resynchronization therapy (CRT) device, a cardiac remodeling control therapy (RCT) device, a drug delivery device, and a biological therapy device. In one embodiment, implantable medical device 510 includes implantable sensors for sensing the signals used by cardiac mechanical dyssynchrony assessment module 410 and pacing parameter optimization module 430. In another embodiment, implantable medical device 510 and lead system 508 each include one or more of the implantable sensors. As shown in FIG. 5, implantable medical device 510 is implanted in a body 502. Lead system 508 provides connections between implantable medical device 510 and a heart 501. In various embodiments, lead system 508 includes leads for sensing physiological signals and delivering pacing pulses, cardioversion/defibrillation shocks, and/or pharmaceutical or other substances. In one embodiment, at least one implantable sensor is incoφorated into a lead of lead system 508 for placement in or about heart 501. In one embodiment, external system 555 is a patient management system including external device 550, network 560, and remote device 570. External device 550 is within the vicinity of implantable medical device 510 and communicates with implantable medical device 510 bi-directionally via telemetry link 540. Remote device 570 is in a remote location and communicates with external device 550 bi-directionally via network 560, thus allowing a user to monitor and treat a patient from a distant location. In another embodiment, external system includes a programmer communicating with implantable medical device 510 bi-directionally via telemetry link 540. System 500 includes system 400 for optimizing pacing parameters based on the cardiac mechamcal dyssynchrony assessment. In one embodiment, system 500 also serves diagnostic and/or other therapeutic p poses by providing the user with heart sound signals indicative of cardiac mechanical dyssynchrony and/or other cardiovascular conditions. The distribution of system 400 in system 500 depends on design and patient management considerations, such as the size and power consumption of each system component and the ability of monitoring the patient in various settings from various locations. In one embodiment, implantable medical device 510 includes the entire system 400. In another embodiment, implantable medical device 510 includes portions of system 400, and external system 555 includes the remaining portions of system 400. One specific embodiment is discussed below with reference to FIG. 6 as an example, but not a limitation. FIG. 6 is a block diagram illustrating one embodiment of a circuit of system 500, including implantable system 505, external system 555, and telemetry link 540 wirelessly coupling the two systems. Implantable system 505 includes lead system 508, heart sound sensor 402, respiratory sensor 404, and implantable medical device 510. Lead system 508 includes pacing leads each having at least one electrode to be placed in a heart chamber. Each pacing lead allows delivery of pacing pulses to, and sensing of cardiac electrical activity from, a cardiac location where the electrode is placed. In one embodiment, lead system 508 includes one or more atrial pacing leads and one or more ventricular pacing leads. The one or more atrial pacing leads include at least one RA pacing lead. The one or more ventricular pacing leads include one or more RV pacing lead and/or one or more LV pacmg leads. In one embodiment, heart sound sensor 402 includes one sensor housed in implantable medical device 510 to sense heart sound signal 302G. In another embodiment, heart sound sensor 402 includes one intracardiac sensor incoφorated into a pacing lead of lead system 508 for placement within a heart chamber to sense heart sound signal 302G. In another embodiment, heart sound sensor 402 includes one intracardiac sensor incoφorated into an RV pacing lead to sense heart sound signal 302R and another intracardiac sensor or epicardial sensor incoφorated into an LV pacing lead to sense heart sound signal 302L. In one embodiment, respiratory sensor 404 is housed in implantable medical device 510. In another embodiment, respiratory sensor 404 is incoφorated into a pacing lead of lead system 508 for placement within a heart chamber. Implantable medical device 510 includes pacing circuit 434, a sensing circuit 603, an implant controller 636, and an implant telemetry module 642. Pacing circuit 434 produces pacing pulses and delivers the pacing pulses to the heart through lead system 508. Sensing circuit 603 senses electrograms indicative of cardiac electrical activities. Implant controller 636 includes at least pacing controller 432, heart sound signal processor 403, and respiratory signal processor 405. Pacing controller 432 controls pacing circuit 434 by executing a selected pacing algorithm using at least the cardiac activities sensed by sensing circuit 603 and pacing parameters programmed into implant controller 636 as inputs. External system 555 includes an external telemetry module 644 and an external controller 652. External controller 652 includes cardiac mechanical dyssynchrony assessment module 410 and pacing parameter optimization module 430. In one embodiment, in which external system 555 includes external device 550, network 560, and remote device 570, remote device 570 includes cardiac mechamcal dyssynchrony assessment module 410 and pacing parameter optimization module 430. This allows long-term therapy optimization performed by the user, or by system 500 automatically, in a location away from the patient's presence. In one embodiment, system 500 provides for therapy optimization on a continuous basis. In another embodiment, system 500 provides for therapy optimization on a predetennined schedule, such as on a periodic basis. In another embodiment, system 500 provides for therapy optimization in response to a change of patient condition detected by or through implantable system 505. In another embodiment, system 500 provides for therapy optimization in response to a command entered by the user. The therapy optimization results in one or more optimal pacing parameter values to be programmed into implant controller 636. Implant telemetry module 642 and external telemetry module 644 support telemetry link 540. Telemetry link 540 is a wireless bidirectional data transmission link. In one embodiment, telemetry link 540 is an inductive couple formed when two coils — one connected to implant telemetry module 642 and the other coimected to external telemetry module 644 — are placed near each other. In this embodiment, the patient or the user places the coil connected to external device 550 on body 502 over implantable medical device 510. In another embodiment, telemetry link 540 is a far-field radio-frequency telemetry link allowing implantable medical device 510 and external device 550 to communicate over a telemetry range that is at least ten feet. In one embodiment, implant telemetry module 642 transmits the heart sound and respiratory signals acquired by implantable system 505, and external telemetry module 644 receives these signals. FIG. 7 is a flow chart illustrating one embodiment of a method for optimizing pacing parameters based on the cardiac mechamcal dyssynchrony assessment. In one embodiment, the method is performed by system 400. One or more heart sound signals indicative of at least SI and S2 are sensed at 700. In one embodiment, the one or more heart sound signals include one or more acceleration signals indicative of the heart's mechanical vibrations. In another embodiment, the one or more heart sound signals include one or more audio signals originated from the heart. In one embodiment, heart sound signal 302G is sensed at 700. hi another embodiment, heart sound signals 302R and 302L are sensed at 700. In another embodiment, both heart sound signal 302G and heart sound signals 302R and 302L are sensed at 700. In one embodiment, a respiratory signal indicative of respiratory cycles each including an inspiratory phase and expiratory phase is also sensed. In one specific embodiment, the respiratory signal includes an impedance signal indicative minute ventilation. The one or more heart sound signals are processed at 710. The process includes envelope-detecting the one or more heart sound signals by rectification and low-pass filtering. In one embodiment, each envelope-detected heart sound signal is ensemble averaged to improve its signal-to-noise ratio. In one embodiment, the respiratory signal is also processed at 710. The process includes detection of expiratory phases. Cardiac mechanical dyssynchrony is assessed based on the one or more heart sound signals at 720. The one or more heart sound signals are received at 722. In one embodiment, the respiratory signal is also received at 722. In one embodiment, only S2G, and/or S2RV and S2LV, that occur during the expiratory phase of the respiratory cycle are used for the assessment of cardiac mechamcal dyssynchrony. SI and S2 are detected from the one or more heart sound signals at 724. In one embodiment, S1G and S2Q are detected from heart sound signal 302G. In another embodiment, SIRV and S2RV are detected from heart sound signal 302R, and SILV and S2LV are detected from heart sound signal 302L. One or more dyssynchrony parameters each indicative of the degree of cardiac mechanical dyssynchrony are produced based on moφhological features of, or related to, SI and S2 at 726. In one embodiment, an automated cardiac mechanical dyssynchrony algorithm is executed to detect moφhological features of detected SI and S2, make measurements related to the moφhological features, and produce the one or more dyssynchrony parameters based on results of the measurements at 726. The moφhological features indicate cardiac valve closure delays. In one embodiment, a first dyssynchrony parameter related to SI and a second dyssynchrony parameter related to S2 are produced at 726. The production of the dyssynchrony parameters includes measuring one or more parameters associated with the moφhological features. In one embodiment, SI width 310 and S2 width 312 are measured from heart sound signal 302G. In another embodiment, SI delay 314 and S2 delay 316 are measured from heart sound signal 302G. SI delay 314 is measured as the time interval between the peak of S1Q associated with mitral valve closure and the peak of S IQ associated with tricuspid valve closure. S2 delay 316 is measured as the time interval between the peak S2Q associated with aortic valve closure and the peak S2G associated with pulmonary valve closure. In another embodiment, SI delay 314 and S2 delay 316 are measured from heart sound signals 302R and 302L. SI delay 314 is measured as the time interval between SIRV and SILV- S2 delay 316 is measured as the time interval between S2RV and S2LV- In another embodiment, at least one time-frequency representation for each of the one or more heart sound signals is produced. The time-frequency representation is produced by, for example, performing one or more of STFT, RID, and WT. One or more dyssynchrony parameters are produced each based on at least one feature in the time-frequency representation. In a further embodiment, a parameter is produced to indicate puhnonary artery pressure based on at least one feature in the time-frequency representation. One or more pacing parameters are optimized at 730, based on the one or more dyssynchrony parameters produced at 726. The one or more parameters are optimized when the one or more dyssynchrony parameters indicate an approximately minimum degree of cardiac mechanical dyssynchrony. In one embodiment, the one or more pacing parameters are optimized based on at least one dyssynchrony parameter produced based on S2 measurements. The optimization is to minimize the time interval between pulmonary valve closure and aortic valve closure. In another embodiment, the one or more pacing parameters are optimized based on at least one dyssynchrony parameter produced based on SI measurements. The optimization is to minimize the time interval between tricuspid valve closure and mitral valve closure. In another embodiment, the one or more pacing parameters are optimized based on dyssynchrony parameters produced based on both S 1 and S2 measurements. If the time interval between pulmonary valve closure and aortic valve closure and the time interval between tricuspid valve closure and mitral valve closure cannot be minimized with the same one or more pacing parameters, the nuiiimization of the time interval between pulmonary valve closure and aortic valve closure has a higher priority. In one embodiment, the one or more pacing parameters are adjusted for an approximately optimal value of each of the one or more dyssynchrony parameters. The approximately optimal value is a value associated with an approximately minimum degree of cardiac mechanical dyssynchrony obtained by adjusting the one or more pacing parameters. Adjusting the one or more pacing parameters includes, but is not limited to, selecting one or more pacing sites to which the pacing pulses are delivered, adjusting one or more AVDs at which ventricular pacing pulses are delivered, and adjusting one or more IVDs at which ventricular pacing pulses are delivered. After each parameter adjustment, a plurality of pacing pulses is delivered to the heart using the one or more adjusted pacing parameters. The optimization process includes repeated parameter adjustments and delivery of pacing pulses using the adjusted parameters until an approximately minimum or otherwise satisfactory degree of cardiac mechanical dyssynchrony is reached. In another embodiment, the one or more pacing parameters are optimized by testing the effects of various combinations of values of the one or more pacing parameters on the one or more dyssynchrony parameters. A plurality of pacing parameter value sets is generated. Each pacing parameter value set includes a value for each of the one or more pacing parameters. Generating the plurality of pacing parameter value sets includes, but is not limited to, generating a plurality of pacing sites or pacing site combinations to which pacing pulses are delivered, generating a plurality of AVDs at which ventricular pacing pulses are delivered, and generating a plurality of IVDs at which ventricular pacing pulses are delivered. After the plurality of pacmg parameter value sets are delivered, a plurality of pacing pulse sequences are delivered. Each sequence includes a plurality of pacing pulses delivered using one pacing parameter value set of the plurality of pacing parameter value sets. An optimal parameter value set is selected from the plurality of pacing parameter value sets. The optimal pacing parameter value set is associated with an approximately optimal value of at least one of the one or more dyssynchrony parameters. The approximately optimal value is associated with a minimum degree of cardiac mechanical dyssynchrony obtained by pacing with the plurality of pacing parameter sets. It is to be understood that the above detailed description is intended to be illustrative, and not restrictive. For example, the method for assessing the cardiac mechanical dyssynchrony can be performed by a non-implantable system. The method for optimizing pacing parameters can apply to optimization of parameters of therapies other than cardiac pacing. Other embodiments, including any possible permutation of the system components discussed in this document, will be apparent to those of skill in the art upon reading and understanding the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims

What is claimed is:
1. A system for analyzing a heart having a first cardiac valve and a second cardiac valve, the system comprising: a heart sound input to receive one or more signals each indicative of heart sounds; a heart sound detector, coupled to the heart soimd input, to detect heart sounds of at least one predetermined type from the one or more signals; and a computer-based heart soimd moφhology analyzer, coupled to the heart sound detector, to produce at least one dyssynchrony parameter indicative of a degree of cardiac mechanical dyssynchrony, the heart sound moφhology analyzer including a heart sound measurement module to measure one or more parameters each based on at least one moφhological feature of the heart sounds of the at least one predetennined type, the at least one moφhological feature indicative of a time interval between closures of the first cardiac valve and the second cardiac valve in one cardiac cycle.
2. The system according to claim 1, wherein the heart sounds of the at least one predetermined type comprise the first heart sounds (SI), and wherein the heart sound moφhology analyzer comprises an SI moφhology analyzer to produce a first dyssynchrony parameter related to SI, the SI moφhology analyzer including an SI measurement module to measure one or more parameters each based on at least an SI moφhological feature indicative a first time interval between a tricuspid valve closure and a mitral valve closure.
3. The system according to claim 1, wherein the heart sounds of the at least one predetermined type comprise the second heart sounds (S2), and wherein the heart sound moφhology analyzer comprises an S2 moφhology analyzer to produce a second dyssynchrony parameter related to S2, the S2 moφhology analyzer including an S2 measurement module to measure one or more parameters each based on at least an S2 moφhological feature indicative of a second time interval between a pulmonary valve closure and an aortic valve closure.
4. The system according to claim 1, wherein the heart sound input receives one or more signals indicative of first heart sounds (SI) and second heart sounds (S2), the heart sound detector detects SI and S2, and the heart sound moφhology analyzer comprises: an SI moφhology analyzer to produce a first dyssynchrony parameter related to SI, the SI moφhology analyzer including an SI measurement module to measure one or more parameters each based on at least an SI moφhological feature indicative a first measured time interval between a tricuspid valve closure and a mitral valve closure; and an S2 moφhology analyzer to produce a second dyssynchrony parameter related to S2, the S2 moφhology analyzer including an S2 measurement module to measure one or more parameters each based on at least an S2 moφhological feature indicative of a second measured time interval between a pulmonary valve closure and an aortic valve closure.
5. The system according to claim 4, wherein the heart sound input comprise: a right- ventricular heart sound input to receive a signal indicative of at least SI sensed from a right ventricle (SIRV) and S2 sensed from the right ventricle (S2RV); and a left-ventricular heart sound input to receive a signal indicative of at least SI sensed from a left ventricle (SILV) and S2 sensed from the left ventricle (S2LV), and wherein: the SI heart sound measurement module comprises an SI delay measurement module to measure an S 1 delay being a time interval between S I V and S ILV; and the S2 heart sound measurement module comprises an S2 delay measurement module to measure an S2 delay being a time interval between S2RV and S2LV-
6. The system according to claim 5, further comprising a first implantable heart sensor adapted to sense the signal indicative of at least SIRV and S2RV and a second implantable heart sensor adapted to sense the signal indicative of at least S ILV and S2LV-
7. The system according to any of claims 4 to 6, wherein: the SI heart sound measurement module comprises an SI width measurement module to measure an SI width; and the S2 heart sound measurement module comprises an S2 width measurement module to measure an S2 width.
8. The system according to any of claims 4 to 6, wherein: the SI heart sound measurement module comprises an SI delay measurement module to measure an SI delay being a time interval between a moφhological feature indicative of the tricuspid valve closure and a moφhological feature indicative of the mitral valve closure; and the S2 heart sound measurement module comprises an S2 delay measurement module to measure an S2 delay being a time interval between a moφhological feature indicative of the pulmonary valve closure and a moφhological feature indicative of the aortic valve closure.
9. The system according to any of claims 4 to 8, further comprising at least one implantable heart sound sensor to sense a signal indicative of at least SI and S2.
10. The system according to claim 9, further comprising an ensemble averaging circuit to ensemble average the signal indicative of at least SI and S2.
11. The system according to any of claims 3 to 10, further comprising a respiratory signal input to receive a respiratory signal indicative of an inspiratory phase and an expiratory phase of a respiratory cycle, and wherein at least the S2 heart sound measurement module is adapted to measure the one or more parameters during the expiratory phase.
12. The system according to claim 11 , further comprising an implantable respiratory sensor to sense the respiratory signal.
13. The system according to claim 12, wherein the implantable respiratory sensor comprises an implantable accelerometer to sense an acceleration signal indicative of inspiration and expiration.
14. The system according to claim 12, wherein the implantable respiratory sensor comprises an implantable impedance sensor to sense an impedance signal indicative of minute ventilation.
15. The system according to any of the preceding claims, wherein the heart sound moφhology analyzer comprises a heart sound time-frequency analyzer to produce at least one time-frequency representation for each of the one or more signals and produce the at least one dyssynchrony parameter based on the at least one time-frequency representation.
16. The system according to claim 15 , wherein the heart sound time- frequency analyzer is adapted to further produce a parameter indicative of pulmonary artery pressure based on at least one feature in the at least one time- frequency representation.
17. The system according to claim 15, wherein the heart sound time- frequency analyzer comprises a short-time Fourier transform (STFT) module.
18. The system according to claim 15, wherein the heart sound time- frequency analyzer comprises a reduced interference (RID) module.
19. The system according to claim 15, wherein the heart sound time- frequency analyzer comprises a wavelet transform (WT) module.
20. The system according to any of the preceding claims, further comprising a pacing parameter optimization module adapted to optimize one or more pacing parameters based on the at least one dyssynchrony parameter.
21. The system according to claim 20, wherein the parameter optimization module is adapted to optimize one or more pacing parameters by adjusting the one or more pacing parameters for an approximately optimal value for the at least one dyssynchrony parameter, and wherein the pacing parameter optimization module comprises a parameter adjustment circuit to adjust the one or more pacing parameters.
22. The system according to claim 21, wherein the parameter adjustment circuit comprises a pacing site selector to select one or more pacing sites to which pacing pulses are delivered.
23. The system according to any of claims 21 and 22, wherein the parameter adjustment circuit comprises an atrioventricular delay (AVD) adjustment circuit to adjust one or more AVDs at which ventricular pacing pulses are delivered.
24. The system according to any of claims 21 to 23 , wherein the parameter adjustment circuit comprises an interventricular delay (IVD) adjustment circuit to adjust one or more IVDs at which ventricular pacing pulses are delivered.
25. The system according to claim 20, further comprising: a pacing circuit to deliver pacing pulses; and a pacing controller, coupled to the pacing circuit and the pacing parameter optimization module, wherein the pacing parameter optimization module comprises a pacing parameter generator to generate a plurality of pacing parameter sets each including one or more adjustable pacing parameters, and wherein the pacing controller is adapted to control a delivery of a plurality of the pacing pulse sequences each including a plurality of pacing pulses delivered using one pacing parameter set of the plurality of pacing parameter sets.
26. The system according to claim 25, wherein the pacing parameter optimization module comprises an efficacy analyzer to relate each pacing parameter set of the plurality of pacing parameter sets to a value of the at least one dyssynchrony parameter.
27. The system according to claim 26, wherein the pacing parameter optimization module further comprises an optimal parameter selector to select an optimal parameter set of the plurality of parameter sets, the optimal parameter set associated with a minimum value of the at least one dyssynchrony parameter.
28. The system according to any of claims 25 to 27, wherein the pacing parameter generator comprises a pacing site generator to generate a plurality of pacing sites to one or more of which the pacing pulses are delivered.
29. The system according to any of claims 25 to 28, wherein the pacing parameter generator comprises an atrioventricular delay (AVD) generator to generate a plurality of AVDs at which ventricular pacing pulses are delivered.
30. The system according to any of claims 25 to 29, wherein the pacing parameter generator comprises an interventricular delay (IVD) generator to generate a plurality of IVDs at which ventricular pacing pulses are delivered.
31. The system according to claim 1 , further comprising: an implantable system including: one or more implantable heart sound sensors to sense the one or more signals each indicative of heart sounds; and an implantable medical device including: an implant controller, coupled to the one or more implantable heart sound sensors, to process the one or more signals; and an implant telemetry module, coupled to the implantable controller, to transmit the one or more signals; an external system communicatively coupled to the implantable medical device, the external system including: an external telemetry module to receive the one or more signals; and an external controller coupled to the external telemetry module, wherein the external controller includes the heart sound input, the heart sound detector, and the heart sound moφhology analyzer.
32. The system according to claim 31, wherein the implantable medical device comprises a hermetically sealed housing, and wherein at least one of the one or more heart sound sensors are housed within the hermetically sealed housing.
33. The system according to claim 31, wherein the implantable medical device comprises a pacmg circuit, and the implantable system further comprises one or more pacing leads coupled to the pacing circuit, wherein at least one of the one or more heart sound sensors is incoφorated into the one of the one or more pacing leads.
34. The system according to claim 33, wherein the one or more pacing leads comprise a right ventricular (RV) pacing lead including at least an RV electrode and a left ventricular (LV) pacing lead include at least an LV electrode, wherein the one or more heart sound sensors comprise an RV heart sound sensor incoφorated into the RV pacing lead near the RV electrode and an LV heart sound sensor incoφorated into the LV pacing lead near the LV electrode.
35. The system according to any of claims 31 to 34, wherein the one or more heart sound sensors comprise at least one accelerometer.
36. The system according to any of claims 31 to 34, wherein the one or more heart sound sensors comprise at least one microphone.
37. The system according to any of claims 31 to 36, wherein the implantable system further comprises a respiratory sensor to sense a respiratory signal indicative of respiratory cycles each including an inspiratory phase and expiratory phase, wherein the heart sound measurement module is adapted to measure the one or more parameters during the expiratory phase.
38. The system according to claim 37, wherein the respiratory sensor comprises a minute ventilation impedance sensor incoφorated onto the implantable medical device.
39. The system according to claim 37, wherein the respiratory sensor comprises an accelerometer incoφorated onto the implantable medical device.
40. The system according to any of claims 31 to 40, wherein the external system comprise a patient monitoring system including: an external device communicatively coupled to the implantable medical device via telemetry; a telecommunication network coupled to the external device; and a remote device, coupled to the telecommunication network, to allow communication with the implantable medical device from a remote location.
41. The system according to claim 40, wherein the heart sound moφhology analyzer is included in the remote device.
42. The system according to any of claims 31 to 41 , wherein the external controller further comprise a pacing parameter optimization module adapted to optimize one or more pacing parameters based on the at least the dyssynchrony parameter.
43. The system according to any of claims 31 to 42, wherein the implantable medical device comprises a cardiac resynchronization therapy (CRT) device.
44. A method for operating a cardiac pacemaker, comprising: receiving one or more heart sound signals indicative of heart sounds of at least one predetermined type; detecting the heart sounds of the at least one predetermined type; producing one or more dyssynchrony parameters each indicative of a degree of cardiac mechanical dyssynchrony based on at least one moφhological feature of the detected heart sounds of the at least one predetermined type by executing an automated cardiac mechamcal dyssynchrony algorithm; and determining one or more pacing parameters for minimizing the degree of cardiac mechanical dyssynchrony based on the one or more dyssynchrony parameters.
45. The method according to claim 44, further comprising sensing the one or more heart sound signals using one or more implantable heart sound sensors.
46. The method according to claim 45, wherein sensing the one or more heart sound signals comprises sensing one or more acceleration signals.
47. The method according to claim 45, wherein sensing the one or more heart sound signals comprises sensing one or more audio signals using one or more microphones.
48. The method according to any of claims 45 to 47, wherein sensing the one or more heart sound signals comprises sensing a heart sound signal from a right ventricle (RV) and sensing another heart sound signal from a left ventricle (LV).
49. The method according to any of claims 45 to 48, further comprising: producing an envelope of each of the one or more heart sound signals by rectifying and low-pass filtering the each of the one or more heart sound signals; and ensemble averaging each of the one or more heart sound signals to improve a signal-to-noise ratio of the each of the one or more heart sound signals.
50. The method according to any of claims 45 to 49, wherein sensing the one or more heart sound signals comprises sensing one or more heart sound signals each indicative of at least first heart somids (SI) and second heart sounds (S2).
51. The method according to claim 50, wherein producing the one or more dyssynchrony parameters comprises producing a first dyssynchrony parameter related to SI and producing a second dyssynchrony parameter related to S2.
52. The method according to claim 51, further comprising: receiving a respiratory signal indicative of respiratory cycles each including an inspiratory phase and expiratory phase; and detecting the expiratory phase, wherein producing the second dyssynchrony parameter related to S2 comprises producing the second dyssynchrony parameter related to S2 based on at least one moφhological feature of S2 detected during the expiratory phase.
53. The method according to claim 52, further comprising sensing the respiratory signal by sensing an thoracic impedance signal indicative minute ventilation.
54. The method according to claim 52, further comprising sensing the respiratory signal by sensing an acceleration signal indicative of inspiration and expiration.
55. The method according to any of claims 51 to 54, wherein producing the first dyssynchrony parameter related to SI comprises measuring an SI width, and producing the second dyssynchrony parameter related to S2 comprises measuring an S2 width.
56. The method according to any of claims 51 to 54, wherein producing the first dyssynchrony parameter related to SI comprises measuring an SI delay representing a time interval between a tricuspid valve closure and a mitral valve closure during one cardiac cycle, and producing the second dyssynchrony parameter related to S2 comprises measuring an S2 delay representing delay between a pulmonary valve closure and an aortic valve closure during one cardiac cycle.
57. The method according to any of claims 51 to 56, wherein producing the first dyssynchrony parameter related to SI comprises producing a time- frequency representation of S 1 and producing a first dyssynchrony parameter associated with at least one feature in the time-frequency representation of SI, and producing the first dyssynchrony parameter related to S2 comprises producing a time-frequency representation of S2 and producing a second dyssynchrony parameter associated with at least one feature in the time- frequency representation of S2.
58. The method according to claim 57, further comprising producing a parameter indicative of pulmonary artery pressure based on at least the time- frequency representation of S2.
59. The method according to claim 57, wherein producing the time- frequency representation of SI and the time-frequency representation of S2 each comprise performing a short-time Fourier transform (STFT).
60. The method according to claim 57, wherein producing the time- frequency representation of S 1 and the time-frequency representation of S2 each comprise performing a reduced interference (RID).
61. The method according to claim 57, wherein producing the time- frequency representation of S 1 and the time-frequency representation of S2 each comprise performing a wavelet transform (WT).
62. The method according to any of claims 51 to 61 , wherein determining the one or more pacing parameters comprises optύnizing the one or more pacing parameters based on at least the second dyssynchrony parameter.
63. The method according to claim 62, wherein determining the one or more pacing parameters further comprises optimizing the one or more pacing parameters based on the first dyssynchrony parameter.
64. The method according to any of claims 44 to 63, further comprising delivering pacing pulses using the one or more pacing parameters.
65. The method according to any of claims 44 to 64, wherein deteimining the one or more pacing parameters comprises adjusting the one or more pacing parameters for an approximately optimal value of each of the one or more dyssynchrony parameters, the approximately optimal value being a value associated with an approximately minimum degree of cardiac mechamcal dyssynchrony obtained by the adjusting the one or more pacing parameters.
66. The method according to claim 65, wherein adjusting the one or more pacing parameters comprises selecting one or more pacing sites to which the pacing pulses are delivered.
67. The method according to any of claims 65 and 66, wherein adjusting the one or more pacmg parameters comprises adjusting one or more atrioventricular delays (AVDs) at which ventricular pacing pulses are delivered.
68. The method according to any of claims 65 to 67, wherein adjusting the one or more pacing parameters comprises adjusting one or more interventricular delays (IVDs) at which ventricular pacing pulses are delivered.
69. The method according to any of claims 44 to 63, wherein determining the one or more pacing parameters comprises: generating a plurality of pacing parameter sets each including one or more adjustable pacing parameters; delivering a plurality of the pacing pulse sequences each including a plurality of pacing pulses delivered using one pacing parameter set of the plurality of pacing parameter sets; associating each pacing parameter set of the plurality of pacing parameter sets to a value of at least one of the one or more dyssynchrony parameters; and selecting an optimal parameter set of the plurality of parameter sets, the optimal parameter set associated with an optimal value of at least one of the one or more dyssynclirony parameters, the optimal value associated with a minimum degree of cardiac mechanical dyssynchrony.
70. The method according to claim 69, wherein generating the plurality of pacing parameter sets comprises generating a plurality of pacing sites to one or more of which the pacing pulses are delivered.
71. The method according to any of claims 69 and 70, wherein generating the plurality of pacing parameter sets comprises generating a plurality of atrioventricular delays (AVDs) at which ventricular pacing pulses are delivered.
72. The method according to any of claims 69 to 71, wherein generating the plurality of pacing parameter sets comprises generating a plurality of interventricular delays (IVDs) at which ventricular pacing pulses are delivered.
PCT/US2005/019773 2004-06-10 2005-06-06 Method and apparatus for individual intraventricular delay optimization WO2005122902A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05758855.0A EP1768566B1 (en) 2004-06-10 2005-06-06 Apparatus for individual intraventricular delay optimization
JP2007527615A JP4939417B2 (en) 2004-06-10 2005-06-06 A system for pacing parameter optimization based on cardiac mechanical asynchrony indicated by heart sounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/865,498 US7209786B2 (en) 2004-06-10 2004-06-10 Method and apparatus for optimization of cardiac resynchronization therapy using heart sounds
US10/865,498 2004-06-10

Publications (1)

Publication Number Publication Date
WO2005122902A1 true WO2005122902A1 (en) 2005-12-29

Family

ID=34972218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/019773 WO2005122902A1 (en) 2004-06-10 2005-06-06 Method and apparatus for individual intraventricular delay optimization

Country Status (4)

Country Link
US (2) US7209786B2 (en)
EP (1) EP1768566B1 (en)
JP (1) JP4939417B2 (en)
WO (1) WO2005122902A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7123962B2 (en) 2002-12-02 2006-10-17 Cardiac Pacemakers, Inc. Phonocardiographic image-based atrioventricular delay optimization
US7209786B2 (en) 2004-06-10 2007-04-24 Cardiac Pacemakers, Inc. Method and apparatus for optimization of cardiac resynchronization therapy using heart sounds
WO2007064260A1 (en) * 2005-11-30 2007-06-07 St. Jude Maedical Ab Implantable medical device with therapy control
WO2007079337A1 (en) * 2005-12-30 2007-07-12 Medtronic, Inc. Method of optimizing data collection and therapy delivery based on respiration
WO2007120082A1 (en) * 2006-04-13 2007-10-25 St. Jude Medical Ab Medical device
WO2008079347A1 (en) * 2006-12-21 2008-07-03 Cardiac Pacemakers, Inc. Implantable device with multiple parameter sets
US7736319B2 (en) 2007-01-19 2010-06-15 Cardiac Pacemakers, Inc. Ischemia detection using heart sound timing
US7780606B2 (en) 2006-03-29 2010-08-24 Cardiac Pacemakers, Inc. Hemodynamic stability assessment based on heart sounds
US7972275B2 (en) 2002-12-30 2011-07-05 Cardiac Pacemakers, Inc. Method and apparatus for monitoring of diastolic hemodynamics
US8000780B2 (en) 2006-06-27 2011-08-16 Cardiac Pacemakers, Inc. Detection of myocardial ischemia from the time sequence of implanted sensor measurements
US8034000B2 (en) 2005-06-08 2011-10-11 Cardiac Pacemakers, Inc. Ischemia detection using a heart sound sensor
US8108034B2 (en) 2005-11-28 2012-01-31 Cardiac Pacemakers, Inc. Systems and methods for valvular regurgitation detection
US8768466B2 (en) 2007-10-12 2014-07-01 Cardiac Pacemakers, Inc. Method and apparatus to trend and optimize an implantable medical device using a patient management system
US8868183B2 (en) 2006-12-21 2014-10-21 Cardiac Pacemakers, Inc. Method and apparatus to implement multiple parameter sets in an implantable device
US8951205B2 (en) 2002-12-30 2015-02-10 Cardiac Pacemakers, Inc. Method and apparatus for detecting atrial filling pressure

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8391989B2 (en) 2002-12-18 2013-03-05 Cardiac Pacemakers, Inc. Advanced patient management for defining, identifying and using predetermined health-related events
US20040122487A1 (en) 2002-12-18 2004-06-24 John Hatlestad Advanced patient management with composite parameter indices
US7468032B2 (en) 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US20040122486A1 (en) * 2002-12-18 2004-06-24 Stahmann Jeffrey E. Advanced patient management for acquiring, trending and displaying health-related parameters
US8043213B2 (en) * 2002-12-18 2011-10-25 Cardiac Pacemakers, Inc. Advanced patient management for triaging health-related data using color codes
US20040122294A1 (en) 2002-12-18 2004-06-24 John Hatlestad Advanced patient management with environmental data
US7983759B2 (en) 2002-12-18 2011-07-19 Cardiac Pacemakers, Inc. Advanced patient management for reporting multiple health-related parameters
US7113825B2 (en) * 2002-05-03 2006-09-26 Cardiac Pacemakers, Inc. Method and apparatus for detecting acoustic oscillations in cardiac rhythm
US7378955B2 (en) * 2003-01-03 2008-05-27 Cardiac Pacemakers, Inc. System and method for correlating biometric trends with a related temporal event
US7248923B2 (en) * 2003-11-06 2007-07-24 Cardiac Pacemakers, Inc. Dual-use sensor for rate responsive pacing and heart sound monitoring
US9050469B1 (en) 2003-11-26 2015-06-09 Flint Hills Scientific, Llc Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals
US7115096B2 (en) 2003-12-24 2006-10-03 Cardiac Pacemakers, Inc. Third heart sound activity index for heart failure monitoring
US7662104B2 (en) 2005-01-18 2010-02-16 Cardiac Pacemakers, Inc. Method for correction of posture dependence on heart sounds
US7917210B2 (en) * 2005-05-13 2011-03-29 Cardiac Pacemakers, Inc. Method and apparatus for cardiac protection pacing
US7894896B2 (en) * 2005-05-13 2011-02-22 Cardiac Pacemakers, Inc. Method and apparatus for initiating and delivering cardiac protection pacing
US8972002B2 (en) 2005-06-01 2015-03-03 Cardiac Pacemakers, Inc. Remote closed-loop titration of decongestive therapy for the treatment of advanced heart failure
US7670298B2 (en) * 2005-06-01 2010-03-02 Cardiac Pacemakers, Inc. Sensing rate of change of pressure in the left ventricle with an implanted device
US7634309B2 (en) * 2005-08-19 2009-12-15 Cardiac Pacemakers, Inc. Tracking progression of congestive heart failure via a force-frequency relationship
EP1933698A2 (en) * 2005-09-16 2008-06-25 The Ohio State University Method and apparatus for detecting intraventricular dyssynchrony
EP1933703A2 (en) * 2005-09-16 2008-06-25 The Ohio State University Method and apparatus for detecting interventricular dyssynchrony
US8920343B2 (en) 2006-03-23 2014-12-30 Michael Edward Sabatino Apparatus for acquiring and processing of physiological auditory signals
US7873410B2 (en) * 2006-04-26 2011-01-18 Medtronic, Inc. Implantable medical device with electromechanical delay measurement for lead position and ventricular
WO2007136554A1 (en) * 2006-05-15 2007-11-29 Mayo Foundation For Medical Education And Research Method for imaging intracavitary blood flow patterns
US8620430B2 (en) 2006-06-30 2013-12-31 Cardiac Pacemakers, Inc. Selection of pacing sites to enhance cardiac performance
US7643879B2 (en) * 2006-08-24 2010-01-05 Cardiac Pacemakers, Inc. Integrated cardiac rhythm management system with heart valve
US20080091239A1 (en) * 2006-10-16 2008-04-17 St. Jude Medical Ab Cardiac assist device and method using epicardially placed microphone
US8725255B2 (en) * 2006-11-17 2014-05-13 Cardiac Pacemakers, Inc. Cardiac resynchronization therapy optimization using cardiac activation sequence information
US20080119749A1 (en) * 2006-11-20 2008-05-22 Cardiac Pacemakers, Inc. Respiration-synchronized heart sound trending
US8096954B2 (en) * 2006-11-29 2012-01-17 Cardiac Pacemakers, Inc. Adaptive sampling of heart sounds
US8615296B2 (en) * 2007-03-06 2013-12-24 Cardiac Pacemakers, Inc. Method and apparatus for closed-loop intermittent cardiac stress augmentation pacing
US8229557B2 (en) 2007-03-29 2012-07-24 Cardiac Pacemakers, Inc. Estimating acute response to cardiac resynchronization therapy
US20080288013A1 (en) * 2007-04-11 2008-11-20 Pacesetter, Inc. Pulmonary pressure monitoring
US7853327B2 (en) * 2007-04-17 2010-12-14 Cardiac Pacemakers, Inc. Heart sound tracking system and method
US8160700B1 (en) * 2007-05-16 2012-04-17 Pacesetter, Inc. Adaptive single site and multi-site ventricular pacing
US8041424B2 (en) * 2007-07-31 2011-10-18 Medtronic, Inc. Cardiac resynchronization therapy for patients with right bundle branch block
US8027724B2 (en) * 2007-08-03 2011-09-27 Cardiac Pacemakers, Inc. Hypertension diagnosis and therapy using pressure sensor
US7731658B2 (en) * 2007-08-16 2010-06-08 Cardiac Pacemakers, Inc. Glycemic control monitoring using implantable medical device
EP2060296B1 (en) * 2007-11-19 2016-08-24 Hollister Incorporated Vapor hydrated catheter assembly and method of making same
US8337404B2 (en) 2010-10-01 2012-12-25 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8571643B2 (en) 2010-09-16 2013-10-29 Flint Hills Scientific, Llc Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex
US8382667B2 (en) 2010-10-01 2013-02-26 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
EP2092885B1 (en) * 2008-02-20 2015-01-28 Ela Medical Device for analysing an endocardiac acceleration signal
WO2010024733A1 (en) 2008-08-28 2010-03-04 St. Jude Medical Ab Implantable medical device and method for determining a myocardial performance parameter
US8417344B2 (en) 2008-10-24 2013-04-09 Cyberonics, Inc. Dynamic cranial nerve stimulation based on brain state determination from cardiac data
CN102333557B (en) * 2009-02-25 2016-03-09 皇家飞利浦电子股份有限公司 The asynchronous detection of patient-ventilator
US8827912B2 (en) 2009-04-24 2014-09-09 Cyberonics, Inc. Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters
US8239028B2 (en) * 2009-04-24 2012-08-07 Cyberonics, Inc. Use of cardiac parameters in methods and systems for treating a chronic medical condition
US8958873B2 (en) * 2009-05-28 2015-02-17 Cardiac Pacemakers, Inc. Method and apparatus for safe and efficient delivery of cardiac stress augmentation pacing
US8140156B2 (en) * 2009-06-30 2012-03-20 Medtronic, Inc. Heart sound sensing to reduce inappropriate tachyarrhythmia therapy
US20110021928A1 (en) * 2009-07-23 2011-01-27 The Boards Of Trustees Of The Leland Stanford Junior University Methods and system of determining cardio-respiratory parameters
US20110066042A1 (en) * 2009-09-15 2011-03-17 Texas Instruments Incorporated Estimation of blood flow and hemodynamic parameters from a single chest-worn sensor, and other circuits, devices and processes
US8812104B2 (en) * 2009-09-23 2014-08-19 Cardiac Pacemakers, Inc. Method and apparatus for automated control of pacing post-conditioning
US8781579B2 (en) 2009-12-08 2014-07-15 St. Jude Medical Ab Implantable medical device for cardiac therapy
US8798746B2 (en) * 2010-01-15 2014-08-05 Cardiac Pacemakers, Inc. Automatic mechanical alternans detection
US8649871B2 (en) 2010-04-29 2014-02-11 Cyberonics, Inc. Validity test adaptive constraint modification for cardiac data used for detection of state changes
US8562536B2 (en) 2010-04-29 2013-10-22 Flint Hills Scientific, Llc Algorithm for detecting a seizure from cardiac data
US8831732B2 (en) 2010-04-29 2014-09-09 Cyberonics, Inc. Method, apparatus and system for validating and quantifying cardiac beat data quality
US8679009B2 (en) 2010-06-15 2014-03-25 Flint Hills Scientific, Llc Systems approach to comorbidity assessment
US8641646B2 (en) 2010-07-30 2014-02-04 Cyberonics, Inc. Seizure detection using coordinate data
US8684921B2 (en) 2010-10-01 2014-04-01 Flint Hills Scientific Llc Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis
US9504390B2 (en) 2011-03-04 2016-11-29 Globalfoundries Inc. Detecting, assessing and managing a risk of death in epilepsy
WO2012135775A1 (en) 2011-04-01 2012-10-04 Medtronic, Inc. Heart failure monitoring
US8725239B2 (en) 2011-04-25 2014-05-13 Cyberonics, Inc. Identifying seizures using heart rate decrease
US9402550B2 (en) 2011-04-29 2016-08-02 Cybertronics, Inc. Dynamic heart rate threshold for neurological event detection
US8617082B2 (en) * 2011-05-19 2013-12-31 Medtronic, Inc. Heart sounds-based pacing optimization
US20120296387A1 (en) 2011-05-19 2012-11-22 Xusheng Zhang Phrenic nerve stimulation detection using heart sounds
US8777874B2 (en) 2011-05-24 2014-07-15 Medtronic, Inc. Acoustic based cough detection
JP5824608B2 (en) * 2011-06-01 2015-11-25 パナソニックIpマネジメント株式会社 Lung sound analyzer
US9549677B2 (en) 2011-10-14 2017-01-24 Flint Hills Scientific, L.L.C. Seizure detection methods, apparatus, and systems using a wavelet transform maximum modulus algorithm
EP2586492B1 (en) 2011-10-24 2014-06-18 St. Jude Medical AB Pacing sequence optimization
US8886311B2 (en) 2012-01-27 2014-11-11 Medtronic, Inc. Techniques for mitigating motion artifacts from implantable physiological sensors
US10492702B2 (en) * 2012-01-31 2019-12-03 The Regents Of The University Of California Real-time cortical mapping
US8965504B2 (en) 2012-03-02 2015-02-24 Cardiac Pacemakers, Inc. Systems and methods of characterizing mechanical activation patterns for rhythm discrimination and therapy
US8996101B2 (en) * 2012-03-12 2015-03-31 Medtronic, Inc. Heart sound sensing to reduce inappropriate tachyarrhythmia therapy
US9095718B2 (en) * 2012-04-04 2015-08-04 Medtronic, Inc. Heart-sounds based adaptive cardiac resynchronization therapy timing parameter optimization system
US10448839B2 (en) 2012-04-23 2019-10-22 Livanova Usa, Inc. Methods, systems and apparatuses for detecting increased risk of sudden death
US8926523B2 (en) 2012-04-27 2015-01-06 Medtronic, Inc. Method and apparatus for cardiac function monitoring
US10220211B2 (en) 2013-01-22 2019-03-05 Livanova Usa, Inc. Methods and systems to diagnose depression
US9717915B2 (en) 2013-03-13 2017-08-01 Cardiac Pacemakers, Inc. System and method for changing device parameters to control cardiac hemodynamics in a patient
US9180301B2 (en) 2013-03-15 2015-11-10 Cardiac Pacemakers, Inc. Estimating electromechanical delay to optimize pacing parameters in RBBB patients
JP6430138B2 (en) * 2014-03-27 2018-11-28 旭化成株式会社 Heart disease determination device, program, medium, and heart disease determination method
US9789320B2 (en) 2014-10-17 2017-10-17 Cardiac Pacemakers, Inc. Method and apparatus for ambulatory optimization of multi-site pacing using heart sounds
WO2016061176A1 (en) 2014-10-17 2016-04-21 Cardiac Pacemakers, Inc. System for optimizing multi-site pacing using heart sounds
US20160235314A1 (en) * 2015-02-17 2016-08-18 National Cheng Kung University Biosensor device, systems and methods thereof
CN107257653B (en) * 2015-02-26 2020-11-24 皇家飞利浦有限公司 Processing device, system and method for processing accelerometer signals for use in monitoring vital signs of a subject
US10327648B2 (en) 2015-04-01 2019-06-25 Siemens Healthcare Gmbh Blood vessel mechanical signal analysis
US11864928B2 (en) * 2016-06-01 2024-01-09 Cardiac Pacemakers, Inc. Systems and methods to detect respiratory diseases using respiratory sounds
CN106236126A (en) * 2016-08-31 2016-12-21 周辉 A kind of portable cardiovascular disease diagnosis alarm device
EP3669936A1 (en) * 2018-12-20 2020-06-24 Sorin CRM SAS Implantable medical device for defibrillation of the heart based on the detection of mechanical vibrations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010889A (en) * 1988-02-04 1991-04-30 Bloodline Technology Intelligent stethoscope
US5012815A (en) * 1989-02-02 1991-05-07 Yale University Dynamic spectral phonocardiograph
US5836987A (en) 1995-11-15 1998-11-17 Cardiac Pacemakers, Inc. Apparatus and method for optimizing cardiac performance by determining the optimal timing interval from an accelerometer signal
US20020151938A1 (en) 2000-11-17 2002-10-17 Giorgio Corbucci Myocardial performance assessment
US6643548B1 (en) * 2000-04-06 2003-11-04 Pacesetter, Inc. Implantable cardiac stimulation device for monitoring heart sounds to detect progression and regression of heart disease and method thereof
US20040106961A1 (en) * 2002-12-02 2004-06-03 Siejko Krzysztof Z. Method and apparatus for phonocardiographic image acquisition and presentation

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586514A (en) 1983-08-10 1986-05-06 Biotronics Instruments Phonoangiographic spectral analysing apparatus
US4981139A (en) 1983-08-11 1991-01-01 Pfohl Robert L Vital signs monitoring and communication system
US5179947A (en) 1991-01-15 1993-01-19 Cardiac Pacemakers, Inc. Acceleration-sensitive cardiac pacemaker and method of operation
US5544661A (en) 1994-01-13 1996-08-13 Charles L. Davis Real time ambulatory patient monitor
US5554177A (en) 1995-03-27 1996-09-10 Medtronic, Inc. Method and apparatus to optimize pacing based on intensity of acoustic signal
US5674256A (en) 1995-12-19 1997-10-07 Cardiac Pacemakers, Inc. Cardiac pre-ejection period detection
SE9603573D0 (en) 1996-09-30 1996-09-30 Pacesetter Ab Implantable medecal device
US5700283A (en) 1996-11-25 1997-12-23 Cardiac Pacemakers, Inc. Method and apparatus for pacing patients with severe congestive heart failure
US5792195A (en) 1996-12-16 1998-08-11 Cardiac Pacemakers, Inc. Acceleration sensed safe upper rate envelope for calculating the hemodynamic upper rate limit for a rate adaptive cardiac rhythm management device
WO1998049290A2 (en) * 1997-04-25 1998-11-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Syndecan interacting proteins and the use thereof
US6193668B1 (en) 1997-11-10 2001-02-27 Medacoustics, Inc. Acoustic sensor array for non-invasive detection of coronary artery disease
US5935081A (en) 1998-01-20 1999-08-10 Cardiac Pacemakers, Inc. Long term monitoring of acceleration signals for optimization of pacing therapy
US7158830B2 (en) 1998-05-08 2007-01-02 Cardiac Pacemakers, Inc. Method and apparatus for optimizing stroke volume during DDD resynchronization therapy using adjustable atrio-ventricular delays
US7110817B2 (en) 1998-05-08 2006-09-19 Cardiac Pacemakers, Inc. Method and apparatus for optimizing ventricular synchrony during DDD resynchronization therapy using adjustable atrio-ventricular delays
US6144880A (en) 1998-05-08 2000-11-07 Cardiac Pacemakers, Inc. Cardiac pacing using adjustable atrio-ventricular delays
US6026324A (en) 1998-10-13 2000-02-15 Cardiac Pacemakers, Inc. Extraction of hemodynamic pulse pressure from fluid and myocardial accelerations
US6044298A (en) 1998-10-13 2000-03-28 Cardiac Pacemakers, Inc. Optimization of pacing parameters based on measurement of integrated acoustic noise
US6371924B1 (en) 1998-11-09 2002-04-16 Medacoustics, Inc. Acoustic window identification
US6440082B1 (en) * 1999-09-30 2002-08-27 Medtronic Physio-Control Manufacturing Corp. Method and apparatus for using heart sounds to determine the presence of a pulse
US6272377B1 (en) 1999-10-01 2001-08-07 Cardiac Pacemakers, Inc. Cardiac rhythm management system with arrhythmia prediction and prevention
US7127290B2 (en) 1999-10-01 2006-10-24 Cardiac Pacemakers, Inc. Cardiac rhythm management systems and methods predicting congestive heart failure status
US6477406B1 (en) 1999-11-10 2002-11-05 Pacesetter, Inc. Extravascular hemodynamic acoustic sensor
US6480733B1 (en) 1999-11-10 2002-11-12 Pacesetter, Inc. Method for monitoring heart failure
US6491639B1 (en) 1999-11-10 2002-12-10 Pacesetter, Inc. Extravascular hemodynamic sensor
US6527729B1 (en) 1999-11-10 2003-03-04 Pacesetter, Inc. Method for monitoring patient using acoustic sensor
US6409675B1 (en) 1999-11-10 2002-06-25 Pacesetter, Inc. Extravascular hemodynamic monitor
US7177686B1 (en) * 1999-11-10 2007-02-13 Pacesetter, Inc. Using photo-plethysmography to monitor autonomic tone and performing pacing optimization based on monitored autonomic tone
US6650940B1 (en) 2000-02-02 2003-11-18 Cardiac Pacemakers, Inc. Accelerometer-based heart sound detection for autocapture
JP2002051997A (en) 2000-08-09 2002-02-19 Nippon Colin Co Ltd Heart sound analyzer
KR100387201B1 (en) 2000-11-16 2003-06-12 이병훈 Diaortic apparatus
US6665564B2 (en) * 2001-05-21 2003-12-16 Cardiac Pacemakers, Inc. Cardiac rhythm management system selecting A-V delay based on interval between atrial depolarization and mitral valve closure
US7079896B1 (en) * 2001-11-26 2006-07-18 Pacesetter, Inc. Methods of automatically optimizing AV delay by way of monitoring the heart sound
US6810287B2 (en) * 2001-12-03 2004-10-26 Cardiac Pacemakers, Inc. Implantable cardiac disease management device with trigger-stored polysomnogram and phonocardiogram
US7127289B2 (en) 2001-12-05 2006-10-24 Cardiac Pacemakers, Inc. Cardiac resynchronization system employing mechanical measurement of cardiac walls
US6915160B2 (en) 2002-02-08 2005-07-05 Cardiac Pacemakers, Inc. Dynamically optimized multisite cardiac resynchronization device
US7043305B2 (en) 2002-03-06 2006-05-09 Cardiac Pacemakers, Inc. Method and apparatus for establishing context among events and optimizing implanted medical device performance
US8391989B2 (en) 2002-12-18 2013-03-05 Cardiac Pacemakers, Inc. Advanced patient management for defining, identifying and using predetermined health-related events
US6963777B2 (en) * 2002-03-13 2005-11-08 Cardiac Pacemakers, Inc. Cardiac rhythm management system and method using time between mitral valve closure and aortic ejection
US6957105B2 (en) * 2002-03-26 2005-10-18 Cardiac Pacemakers, Inc. Method and apparatus for detecting oscillations in cardiac rhythm with electrogram signals
US7113825B2 (en) * 2002-05-03 2006-09-26 Cardiac Pacemakers, Inc. Method and apparatus for detecting acoustic oscillations in cardiac rhythm
US7400928B2 (en) 2002-10-11 2008-07-15 Cardiac Pacemakers, Inc. Methods and devices for detection of context when addressing a medical condition of a patient
US7123962B2 (en) * 2002-12-02 2006-10-17 Cardiac Pacemakers, Inc. Phonocardiographic image-based atrioventricular delay optimization
US7972275B2 (en) 2002-12-30 2011-07-05 Cardiac Pacemakers, Inc. Method and apparatus for monitoring of diastolic hemodynamics
US7139609B1 (en) * 2003-01-17 2006-11-21 Pacesetter, Inc. System and method for monitoring cardiac function via cardiac sounds using an implantable cardiac stimulation device
US6885889B2 (en) * 2003-02-28 2005-04-26 Medtronic, Inc. Method and apparatus for optimizing cardiac resynchronization therapy based on left ventricular acceleration
US7079895B2 (en) * 2003-04-25 2006-07-18 Medtronic, Inc. Cardiac pacing for optimal intra-left ventricular resynchronization
US7142919B2 (en) * 2003-10-24 2006-11-28 Medtronic, Inc. Reconfigurable, fault tolerant multiple-electrode cardiac lead systems
US9002452B2 (en) * 2003-11-07 2015-04-07 Cardiac Pacemakers, Inc. Electrical therapy for diastolic dysfunction
US7431699B2 (en) 2003-12-24 2008-10-07 Cardiac Pacemakers, Inc. Method and apparatus for third heart sound detection
US7115096B2 (en) 2003-12-24 2006-10-03 Cardiac Pacemakers, Inc. Third heart sound activity index for heart failure monitoring
US7203541B2 (en) * 2004-03-12 2007-04-10 Medtronic, Inc. Real-time optimization of right to left ventricular timing sequence in bi-ventricular pacing of heart failure patients
US7209786B2 (en) 2004-06-10 2007-04-24 Cardiac Pacemakers, Inc. Method and apparatus for optimization of cardiac resynchronization therapy using heart sounds
US7269458B2 (en) * 2004-08-09 2007-09-11 Cardiac Pacemakers, Inc. Cardiopulmonary functional status assessment via heart rate response detection by implantable cardiac device
US7922669B2 (en) 2005-06-08 2011-04-12 Cardiac Pacemakers, Inc. Ischemia detection using a heart sound sensor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010889A (en) * 1988-02-04 1991-04-30 Bloodline Technology Intelligent stethoscope
US5012815A (en) * 1989-02-02 1991-05-07 Yale University Dynamic spectral phonocardiograph
US5836987A (en) 1995-11-15 1998-11-17 Cardiac Pacemakers, Inc. Apparatus and method for optimizing cardiac performance by determining the optimal timing interval from an accelerometer signal
US6643548B1 (en) * 2000-04-06 2003-11-04 Pacesetter, Inc. Implantable cardiac stimulation device for monitoring heart sounds to detect progression and regression of heart disease and method thereof
US20020151938A1 (en) 2000-11-17 2002-10-17 Giorgio Corbucci Myocardial performance assessment
US20040106961A1 (en) * 2002-12-02 2004-06-03 Siejko Krzysztof Z. Method and apparatus for phonocardiographic image acquisition and presentation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BULGRIN J R; RUBAL B J; THOMPSON C R; MOODY J M: "Comparison of short-time Fourier, wavelet and time-domain analyses of intracardiac sounds.", BIOMEDICAL SCIENCES INSTRUMENTATION, vol. 29, 1993, USA, pages 465 - 472, XP008052978 *
LEATHAM A.: "Splitting of the first and second heart sounds.", LANCET, vol. 267, no. 6839, 25 September 1954 (1954-09-25), pages 607 - 614, XP008052982, ISSN: 0140-6736 *
OBAIDAT M S ET AL: "Performance of the short-time Fourier transform and wavelet transform to phonocardiogram signal analysis", APPLIED COMPUTING: TECHNOLOGICAL CHALLENGES OF THE 1990'S. PROCEEDINGS OF THE 1992 ACM/SIGAPP SYMPOSIUM ON APPLIED COMPUTING ACM NEW YORK, NY, USA, 1992, pages 856 - 862, XP002349785, ISBN: 0-89791-502-X *
WOOD J C ET AL: "TIME-FREQUENCY TRANSFORMS: A NEW APPROACH TO FIRST HEART SOUND FREQUENCY DYNAMICS", IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, IEEE SERVICE CENTER, PISCATAWAY, NJ, US, vol. 39, no. 7, 1 July 1992 (1992-07-01), pages 730 - 740, XP000294410, ISSN: 0018-9294 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7123962B2 (en) 2002-12-02 2006-10-17 Cardiac Pacemakers, Inc. Phonocardiographic image-based atrioventricular delay optimization
US8403860B2 (en) 2002-12-30 2013-03-26 Cardiac Pacemakers, Inc. Method and apparatus for detecting atrial filling pressure
US7972275B2 (en) 2002-12-30 2011-07-05 Cardiac Pacemakers, Inc. Method and apparatus for monitoring of diastolic hemodynamics
US8636669B2 (en) 2002-12-30 2014-01-28 Cardiac Pacemakers, Inc. Method and apparatus for monitoring of diastolic hemodynamics
US8951205B2 (en) 2002-12-30 2015-02-10 Cardiac Pacemakers, Inc. Method and apparatus for detecting atrial filling pressure
US8048001B2 (en) 2002-12-30 2011-11-01 Cardiac Pacemakers, Inc. Method and apparatus for detecting atrial filling pressure
US7953484B2 (en) 2004-06-10 2011-05-31 Cardiac Pacemakers, Inc. Method and apparatus for optimization of cardiac resynchronization therapy using heart sounds
US7209786B2 (en) 2004-06-10 2007-04-24 Cardiac Pacemakers, Inc. Method and apparatus for optimization of cardiac resynchronization therapy using heart sounds
US8034000B2 (en) 2005-06-08 2011-10-11 Cardiac Pacemakers, Inc. Ischemia detection using a heart sound sensor
US8758260B2 (en) 2005-06-08 2014-06-24 Cardiac Pacemakers, Inc. Ischemia detection using a heart sound sensor
US8108034B2 (en) 2005-11-28 2012-01-31 Cardiac Pacemakers, Inc. Systems and methods for valvular regurgitation detection
WO2007064260A1 (en) * 2005-11-30 2007-06-07 St. Jude Maedical Ab Implantable medical device with therapy control
US7623917B2 (en) 2005-12-30 2009-11-24 Medtronic, Inc. Method of optimizing data collection and therapy delivery based on respiration
WO2007079337A1 (en) * 2005-12-30 2007-07-12 Medtronic, Inc. Method of optimizing data collection and therapy delivery based on respiration
US7780606B2 (en) 2006-03-29 2010-08-24 Cardiac Pacemakers, Inc. Hemodynamic stability assessment based on heart sounds
WO2007120082A1 (en) * 2006-04-13 2007-10-25 St. Jude Medical Ab Medical device
US8000780B2 (en) 2006-06-27 2011-08-16 Cardiac Pacemakers, Inc. Detection of myocardial ischemia from the time sequence of implanted sensor measurements
WO2008079347A1 (en) * 2006-12-21 2008-07-03 Cardiac Pacemakers, Inc. Implantable device with multiple parameter sets
US8868183B2 (en) 2006-12-21 2014-10-21 Cardiac Pacemakers, Inc. Method and apparatus to implement multiple parameter sets in an implantable device
US7736319B2 (en) 2007-01-19 2010-06-15 Cardiac Pacemakers, Inc. Ischemia detection using heart sound timing
US8768466B2 (en) 2007-10-12 2014-07-01 Cardiac Pacemakers, Inc. Method and apparatus to trend and optimize an implantable medical device using a patient management system

Also Published As

Publication number Publication date
US20070162080A1 (en) 2007-07-12
US7209786B2 (en) 2007-04-24
JP4939417B2 (en) 2012-05-23
US20060020294A1 (en) 2006-01-26
EP1768566B1 (en) 2016-03-30
US7953484B2 (en) 2011-05-31
JP2008502444A (en) 2008-01-31
EP1768566A1 (en) 2007-04-04

Similar Documents

Publication Publication Date Title
US7209786B2 (en) Method and apparatus for optimization of cardiac resynchronization therapy using heart sounds
US11305124B2 (en) System and method for pacing parameter optimization using heart sounds
US7559901B2 (en) Determining a patient's posture from mechanical vibrations of the heart
US7248923B2 (en) Dual-use sensor for rate responsive pacing and heart sound monitoring
US7951087B2 (en) Method for correction of posture dependence on heart sounds
US10595813B2 (en) Method and apparatus for monitoring cardiac and respiratory conditions using acoustic sounds
EP1581302B1 (en) Apparatus for monitoring of diastolic hemodynamics
US5554177A (en) Method and apparatus to optimize pacing based on intensity of acoustic signal
US6949075B2 (en) Apparatus and method for detecting lung sounds using an implanted device
US8876727B2 (en) Phrenic nerve stimulation detection using heart sounds
US20120271186A1 (en) Third heart sound activity index for heart failure monitoring
US8679024B2 (en) System and method for deriving respiration from intracardiac electrograms (EGM) or ECG signals
US20220008733A1 (en) Sensor-based phrenic nerve stimulation detection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007527615

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005758855

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005758855

Country of ref document: EP